

CURRICULUM VITAE

Henry Richard Kranzler

Primary Office:

Department of Psychiatry
Treatment Research Center
3535 Market Street, Rm. 543
Philadelphia, PA 19104

Home:

1938 Panama Street
Philadelphia, PA 19103

Phone: (215) 746-1943

Fax: (215) 746-7350

E-Mail: kranzler@pennterms.edu

Mobile Telephone: (860) 573-2184

Secondary Office:

Mental Illness Research, Education and Clinical Center
Crescenz Veterans Affairs Medical Center, Rm. B214
3900 Woodland Ave.
Philadelphia, PA 19104
Phone: (215) 823-5800, ext. 6865
E-mail: henry.kranzler@va.gov

PERSONAL

Born on February 11, 1950 in Newark, NJ

Married, three children

EDUCATION AND TRAINING

Monmouth University
West Long Branch, N.J.

Bachelor of Arts *summa cum laude* in
Anthropology, May 1976

Rutgers University
New Brunswick, NJ

Master of Arts in Anthropology
May 1980

UMDNJ–Robert Wood Johnson Medical School
Piscataway, NJ

Doctor of Medicine
May 26, 1982

University of Connecticut School of Medicine
Farmington, CT

Psychiatric Residency
July 1, 1982–June 30, 1986

University of Connecticut School of Medicine
Farmington, CT

NIAAA Postdoctoral Fellowship in
Alcohol Studies
July 1, 1984–June 30, 1987

ACADEMIC POSITIONS

University of Connecticut
School of Medicine

Instructor, Department of
Psychiatry, 1986–1987

University of Connecticut
School of Medicine

Assistant Professor, Department
of Psychiatry, 1987–1992

University of Connecticut

Associate Professor, Department

School of Medicine	of Psychiatry, 1992–1998
University of Connecticut School of Medicine	Professor (with tenure), Department of Psychiatry, 1998–2010
University of Connecticut School of Medicine	Professor, Department of Genetics and Developmental Biology, 2010
University of Connecticut School of Medicine	Emeritus Professor of Psychiatry and Genetics and Developmental Biology, 2010–present
Perelman School of Medicine of the University of Pennsylvania	Professor (with tenure), Department of Psychiatry, 2010–present

LICENSURE AND CERTIFICATION

1984: National Board of Medical Examiners, Identification No. 242822
1984–2011: Connecticut License, Registration No. 25712
1987–present: American Board of Psychiatry and Neurology, Certificate No. 29539
1993–2003: American Board of Psychiatry and Neurology, Added Qualifications in Addiction
Psychiatry, Certificate No. 230 (re-certification, 2003-2013)
2010–present: Pennsylvania License, Registration No. MD440988

HONORS

1975 Lambda Sigma Tau and Lambda Alpha Honor Societies
1976 Who's Who in American Universities and Colleges
1981 Alpha Omega Alpha (President of the Alpha Chapter of New Jersey) (1981)
George F. Smith Scholarship of the Foundation of the UMDNJ
1983–1984 Group for the Advancement of Psychiatry, Sol W. Ginsburg Fellowship
1985–1987 Group for the Advancement of Psychiatry, Ethel Ginsburg Fellowship
1986 Award for Academic Achievement, Psychiatric Residency Program, University of
Connecticut School of Medicine
1988 Mead-Johnson/American College of Neuropsychopharmacology Travel Award
1991 Committee on Problems of Drug Dependence Travel Fellowship
2006 Frontiers of Science Lectureship, American Psychiatric Association Meeting, Toronto,
Canada
2007 Frank J. MacDonell Lectureship, Department of Psychiatry, University of Michigan
School of Medicine
2008 Medical Sciences Graduate Students' Association Lectureship, University of Calgary
2009 Distinguished Fellow, American Academy of Addiction Psychiatry
2009 Fellow, American College of Neuropsychopharmacology
2002–2009 Best Doctors in America
2010 Alumnus of the Year, Monmouth University
2013 Keynote Speaker, Visions in Pharmacology, University of Toronto
2014 Editor-in-Chief, *Alcoholism: Clinical and Experimental Research*
2014 James H. Tharp Award for Alcoholism Research, American Society of Addiction
Medicine
2014 Dan Anderson Research Award, Hazelden Betty Ford Foundation
2015 Scott Mackler Award for Excellence in Substance Abuse Teaching, University of

- Pennsylvania Perelman School of Medicine
2015 Leroy W. Davis Memorial Alcohol Lecture, Department of Psychiatry, Eastern Virginia Medical School, Norfolk, VA
2017 Orr Lecture in Addiction Psychiatry, Department of Psychiatry and Behavioral Sciences, Vanderbilt University, Nashville, TN

GRANTS AND CONTRACTS

National Institutes of Health and Department of Veterans Affairs

Current

1. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “2/2 pharmacogenetic study (Ondansetron treatment of alcohol dependence)” (R01 AA021164): July 1, 2012–June 30, 2019 (NCE) (\$1,353,107 in direct costs).
2. National Cancer Institute. Principal Investigator for “Placebo-controlled trial of bupropion for smoking cessation in pregnant women” (R01 CA184315): August 15, 2014–July 31, 2019 (\$2,527,115 in direct costs).
3. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Pharmacogenetic analysis of topiramate treatment of AUD” (R01 AA023192): August 15, 2014–July 31, 2019 (\$1,601,207 in direct costs).
4. VA Office of Research and Development. Co-Principal Investigator for “Genetic Vulnerability for Sustained Multi-Substance Use in MVP” (I01 BX003341): November 1, 2016–October 31, 2018 (\$300,000 in direct costs).
5. National Institute on Drug Abuse. Co-investigator for “Genetics of opioid dependence” (R01 DA12690, J. Gelernter, PI): October 1, 2013–September 30, 2018.
6. National Institute on Drug Abuse. Co-investigator for “Quantitative methods to subtype drug dependence and detect novel genetic variants” (R01 DA37349; J. Bi, PI): February 1, 2015–November 30, 2018.
7. Department of Defense. Co-investigator for “Preventing risky drinking in veterans treated with prescription opioids” (W81XWH-14-1-0060; J. McKay, Principal Investigator): April 1, 2014–March 31, 2019.
8. VA Office of Research and Development. Co-Investigator for “Pharmacogenetic study of opioid agonist treatments in MVP” (I01 CX001734-01) December 1, 2017–November 30, 2019. (\$300,000 in direct costs).
9. National Institute on Alcohol Abuse and Alcoholism. Co-investigator for “Mechanisms of behavior change in alcohol use disorder treatment” (R01AA025539; K. Witkiewitz, PI) April 1, 2017 – March 31, 2022.
10. VA Office of Research and Development. Co-Investigator for “PRIME Care (Precision Medicine in Mental Health Care)” (SDR 16-348, D. Oslin, PI). October 1, 2016 – September 30, 2022.

Completed

1. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Pharmacogenetic analysis of topiramate treatment of AUD” (R01 AA023192 Administrative Supplement): November 15, 2015–November 14, 2016 (\$95,000 in direct costs).

2. National Institute on Drug Abuse. Principal Investigator for University of Pennsylvania component of “Deep sequencing studies for cannabis and stimulant dependence” (R01 DA030976): September 30, 2010–May 31, 2016 (NCE) (\$216,925 in direct costs). University of North Carolina-Chapel Hill, K. Wilhelmsen, Principal Investigator.
3. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for University of Pennsylvania component of “Genetics of alcohol dependence in African-Americans” (R01 AA017535): September 15, 2009–August 31, 2015 (\$547,074 in total direct costs). Yale University, J. Gelernter, Principal Investigator.
4. National Institute on Alcohol Abuse and Alcoholism. Co-Principal Investigator for University of Pennsylvania component of “Genetics of Alcohol Dependence in American Populations” (R01 AA011330): March 1, 2009–February 28, 2015 (\$447,514 in total direct costs). Yale University, J. Gelernter, Principal Investigator.
5. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Novel Approaches to Alcoholism Pharmacotherapy and Risk” (K24 AA013736): May 1, 2008–September 30, 2014 (\$739,097 in total direct costs; currently in no-cost extension).
6. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Topiramate Treatment for Heavy Drinkers”: December 1, 2007 – November 30, 2012 (\$960,914 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P60 AA03510), University of Connecticut Health Center, V. Hesselbrock, Principal Investigator.
7. National Institute on Drug Abuse. Principal Investigator for “Genetics of Cocaine Dependence” (R01 DA18432): June 1, 2006 – March 31, 2012 (\$2,536,393 in total direct costs, including no-cost extension).
8. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Sertraline Pharmacotherapy for Alcoholism Subtypes” (R01 AA13631): June 5, 2003 – May 31, 2009 (\$1,374,033 in total direct costs, including a one-year, no-cost extension)
9. National Institute on Alcohol Abuse and Alcoholism. Co-investigator for “Zonisamide versus Placebo in the Treatment of Alcohol Dependence”: December 1, 2007 – November 30, 2009 (\$84,790 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P60 AA03510), University of Connecticut Health Center, V. Hesselbrock, Principal Investigator.
10. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Novel Approaches to Alcoholism Pharmacotherapy and Risk” (K24 AA13736): September 1, 2002 – July 31, 2008 (\$659,738 in total direct costs, including a one-year, no-cost extension).
11. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Targeted Naltrexone for Problem Drinkers”: December 1, 2002 – November 30, 2007, (\$1,095,638 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P50 AA03510), University of Connecticut Health Center, V. Hesselbrock, Principal Investigator.
12. National Center for Research Resources. Principal Investigator for “Planning for a CTSA Application at the University of Connecticut” (P20 RR023507): September 1, 2006 – August 31, 2007 (\$149,223 in total direct costs).

13. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for University of Connecticut Health Center component of “Family-Controlled Linkage Disequilibrium Studies in Alcoholism” (R01 AA11330): May 1, 2002 – April 30, 2007 (\$616,177 in total direct costs). Yale University, J. Gelernter, Principal Investigator.
14. National Institute on Drug Abuse. Principal Investigator for University of Connecticut Health Center component of “Genetics of Cocaine Dependence” (R01 DA12849): September 30, 1999 – September 29, 2004 (\$797,000 in total direct costs). Yale University, J. Gelernter, Principal Investigator.
15. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “The Effect of Finasteride on Alcohol-Induced Mood and Behavior”: December, 2002 - November, 2004 (\$137,416 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P50-AA03510), University of Connecticut Health Center, V. Hesselbrock, Principal Investigator.
16. National Institute on Drug Abuse. Principal Investigator for University of Connecticut Health Center component of “Genetics of Cocaine-Induced Psychosis” (R01-DA12422): September 1, 2000 – August 31, 2004 (\$211,000 in total direct costs). Yale University, J. Cubells, Principal Investigator.
17. National Institute on Drug Abuse. Principal Investigator for University of Connecticut Health Center component of “Genetics of Opioid Dependence” (R01 DA12690): August 5, 2000 - July 31, 2005 (\$796,000 in total direct costs). Yale University, J. Gelernter, Principal Investigator.
18. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Targeted Naltrexone for Early Problem Drinkers” (R01 AA11062): September 1, 1996 – August 31, 2002 (\$1,031,430 in total direct costs).
19. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “New Approaches to the Pharmacotherapy of Alcoholism” (K02 AA00239): April, 1997 - March, 2002 (\$446,478 in total direct costs).
20. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for "Depot Naltrexone Treatment of Alcohol Dependence": December, 1997 - November, 2001, (\$633,256 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P50 AA03510), University of Connecticut Health Center, V. Hesselbrock, Principal Investigator.
21. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for University of Connecticut Health Center component of “5-HT and DA System Genes in Alcohol Dependence” (R01 AA11330): December, 1996 - November, 1999 (\$155,041 in total direct costs). Yale University, J. Gelernter, Principal Investigator.
22. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for "Comparison of Nefazadone, Naltrexone, and Placebo in Combination with Relapse Prevention Treatment of Alcoholism": December, 1992 - November, 1997, (\$786,111 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P50 AA03510), University of Connecticut Health Center, V. Hesselbrock, Principal Investigator.
23. National Institute on Drug Abuse. Principal Investigator for "Molecular Genetics of Drug Abuse: Application of Haplotype Relative Risk” (R21 DA10242): September, 1995 - August, 1997 (\$171,000 in total direct costs).

24. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for "Matching Alcoholic Subtypes to Specific Medications" (K20 AA00143): February, 1992 - January, 1997 (\$554,193 in total direct costs).
25. National Institute on Drug Abuse. Principal Investigator for "Placebo-Controlled Trial of Naltrexone for Treatment of Cocaine and Alcohol Abuse": August, 1995 - July, 1996 (\$127,295 in total direct costs). Competitive Supplement to the Clinical Research Center for Opioid and Cocaine Abuse (P50 DA04060), Yale University, T. Kosten, Principal Investigator.
26. National Institute on Drug Abuse. Principal Investigator for University of Connecticut Health Center component of "Diagnosis of Drug Abuse: Clinical Implications" (R01 DA05592): August, 1992 - July 31, 1996 (\$389,106 in total direct costs). Yale University, B. Rounsaville, Principal Investigator.
27. National Institute on Drug Abuse. Principal Investigator for "Carbamazepine Treatment of Cocaine Dependence" and "Placebo-Controlled Trial of Naltrexone for Treatment of Alcohol and Cocaine Abuse": August, 1991 - July, 1995 (\$534,981 in total direct costs). Component of the Clinical Research Center for Opioid and Cocaine Abuse (P50 DA04060), Yale University, T. Kosten, Principal Investigator.
28. National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for "Controlled Trials of Buspirone and Fluoxetine in the Prevention of Relapse in Alcoholics": December, 1987 - December, 1992 (\$839,579 in total direct costs). Component of the Center for Research in the Etiology and Treatment of Alcohol Dependence (P50 AA03510), R. Meyer, Principal Investigator.

Foundations, Industry, and Universities

1. Accelerator Program, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine. "Molecular Genetic Prediction of Opioid Analgesic Dosage Requirements in African-American Orthopaedic Surgery Patients." July 1, 2017 – June 30, 2018 (\$60,000 in direct costs).
2. Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine. "Pilot Study of Topiramate to Reduce Drinking in HIV+ Heavy Drinkers." July 1, 2012 – June 30, 2013 (\$20,000 in direct costs).
3. Bristol-Myers Squibb Company. "Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol": February 1, 2004 – February 28, 2007 (\$41,450 in total direct costs).
4. Ortho-McNeil Pharmaceuticals. Principal Investigator for "A Multicenter, Randomized, Double Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence": May 1, 2004 – August 1, 2006.
5. Bristol-Myers Squibb Company. "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence from Alcohol in Subjects with Alcoholism": May 1, 2004 - April 30, 2005.
6. Alkermes, Inc. Principal Investigator for "A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Medisorb Naltrexone in Alcohol Dependent Adults": March 1, 2002 – June 1, 2004 (\$295,610 in total direct costs).

7. DrugAbuse Sciences. Principal Investigator for "Safety and Efficacy of Naltrel™ in Treatment of Alcohol Dependence": March 1, 2002 - February 28, 2003 (\$107,500 in total direct costs).
8. Bristol-Myers Squibb. Principal Investigator for "Double-Blind, Placebo-Controlled Trial of Nefazodone in Patients with Comorbid Alcohol Dependence and Major Depression": September, 1999 - August, 2002 (\$20,000 in total direct costs).
9. Contral Pharma. Principal Investigator for "CPH-101 In Heavy Alcohol Drinkers With Impaired Control: A 12+40 week Placebo Controlled Dose Response Study": February, 2000 - June, 2001 (\$181,000 in total direct costs).
10. Pfizer Pharmaceuticals. Principal Investigator for "Genetic Polymorphisms in Patients With Comorbid Alcohol Dependence and Major Depression": July, 1998 - June, 1999 (\$8,500 in total direct costs).
11. Pfizer Pharmaceuticals. Principal Investigator for "Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Depression and a DSM-IV Diagnosis of Alcohol Dependence": July, 1996 - June, 1999 (\$403,000 in total direct costs).
12. Liplha Pharmaceuticals. Principal Investigator for "Acamprosate in Patients with Alcohol Dependence: A Double-Blind, Placebo-Controlled Safety and Efficacy Study at Two Active Dose Levels": August, 1997 – December, 1998 (\$224,000 in total direct costs).
13. Pharmacia & Upjohn Pharmaceuticals. Principal Investigator for "Study of CDTECT EIA, an Enzyme Immunoassay for Quantitative Measurement of Carbohydrate Deficient Transferrin in Human Serum, as a Tool for Monitoring Abstinence and Relapse in Patients Treated for Alcohol Dependence": September, 1996-August, 1997 (\$33,000 in total direct costs).
14. Janssen Research Foundation. Principal Investigator for "Ritanserin in the Treatment of Alcohol Dependence": June, 1993 - November, 1994 (\$207,000 in total direct costs).
15. Sandoz Pharmaceuticals Corp. Principal Investigator for "Abecarnil vs. Diazepam for Treatment of Alcohol Withdrawal": June, 1992 - November, 1992 (\$35,000 in total direct costs).
16. University of Connecticut Health Center Research Advisory Committee. Principal Investigator for "Cocaine Craving: Assessment and Treatment": January - December 1989 (\$21,850 in total direct costs).

COMMITTEE MEMBERSHIP

University of Connecticut Health Center

Executive Committee Alcohol Research Center	1990–2010
Executive Committee Department of Psychiatry	1993–2010
Scientific Advisory Committee General Clinical Research Center	1992–1997 1997–2009 (<i>ex officio</i>)
Executive Committee General Clinical Research Center	1998–2010

Senior Appointments and Promotions Committee Department of Psychiatry	1998–2010
Institutional Review Board (Vice-Chairman)	1989–1999
(Chairman)	1994–1995
	1995–1997
Human Subjects Protection Office Executive Council	2001–2009

CLINICAL ADMINISTRATION

University of Connecticut Health Center

Division of Adult Psychiatry Department of Psychiatry	Director of Inpatient Services 1995–1996
Division of Addictive Disorders Department of Psychiatry	Director 1991–1996
Alcohol & Drug Abuse Treatment Center Department of Psychiatry	Psychiatric Director 1987–1990

RESEARCH ADMINISTRATION

University of Connecticut Health Center

Lowell P. Weicker, Jr. Clinical Research Center	Program Director, 2005–2009 Assoc. Prg. Director, 1997–2004
Office of Clinical and Translational Research	Associate Dean, 2005–2006 Assistant Dean, 2004–2005
Alcohol Research Center Department of Psychiatry	Associate Scientific Director 1993–2010
Clinical Research and Evaluation Unit Department of Psychiatry	Medical Director 1988–2010

University of Pennsylvania Perelman School of Medicine (PSOM) and Crescenz VAMC

Center for Studies of Addiction (PSOM)	Director, 2013–present
VISN 4 Mental Illness Research, Education, and Clinical Center (VAMC)	Co-Associate Director of Research 2010–present
Addictions Faculty Search Committee, Neuroscience of Behavior Initiative (PSOM)	Chair, 2012–2013

EDUCATION ADMINISTRATION

University of Connecticut Health Center

Residency Training Program in Addiction Psychiatry	Director, 1997–2000
--	---------------------

Postdoctoral Training Program in Alcohol Studies

Assistant Director, 1986–1990

Philadelphia VAMC

Post-doctoral Research Training Program for Physicians
VISN 4 Mental Illness Research, Education, and Clinical
Center

Director, 2010–present

RESEARCH MENTORSHIP

2017–present

James Rotenberg, M.D., Postdoctoral Fellow, VISN 4
Mental Illness Research, Education, and Clinical Center,
Crescenz VAMC

2016–present

Michelle Naps, M.D., Postdoctoral Fellow, VISN 4 Mental
Illness Research, Education, and Clinical Center, Crescenz
VAMC

2015–present

Brenda Curtis, Ph.D., Assistant Professor, Department of
Psychiatry, University of Pennsylvania Perelman School of
Medicine

2014–present

Subhajt Chakravorty, M.D., Staff Physician, Philadelphia
Veterans Affairs Medical Center (Co-mentor for Career
Development Award-2)

2013–present

Reagan Wetherill, Ph.D., Assistant Research Professor,
Department of Psychiatry, University of Pennsylvania
Perelman School of Medicine (Primary mentor K23 Award)

2013–present

Rebecca Ashare, Ph.D., Assistant Professor, Department of
Psychiatry, University of Pennsylvania Perelman School of
Medicine (Co-mentor for K23 award)

2013–2015

Amy Hart, Ph.D., NIDA Postdoctoral Fellow, University of
Pennsylvania Perelman School of Medicine

2011–2012

David Leach, M.D., Postdoctoral Fellow, VISN 4 Mental
Illness Research, Education, and Clinical Center,
Philadelphia VAMC

2009–2015

Jermaine Jones, Ph.D., Assistant Professor, Department of
Psychiatry, Columbia University (Co-mentor for K01 award)

2008–2013

Adam Leventhal, Ph.D., Assistant Professor, Departments of
Preventive Medicine and Psychology, University of Southern
California (Co-mentor for K23 award)

2008–2013

Andrew Chen, M.D., Ph.D., Assistant Professor, Department
of Psychiatry, Columbia University (Co-mentor for K23
award)

2007–2012 Magdalena Uhart, M.D., Assistant Professor, Department of Medicine, Johns Hopkins University; currently Assistant Professor of Medicine, University of California-Los Angeles (Co-mentor for K23 award)

2006–2008 Mark Niciu, M.D./Ph.D. Student, University of Connecticut School of Medicine

2004–2013 Albert Arias, M.D., Psychiatric Resident (2004-2006), Assistant Professor of Psychiatry, University of Connecticut School of Medicine (2006 – 2011) (Mentor for K23 award); currently Assistant Professor of Psychiatry, Yale University (2011 – 2013) (Co-mentor for K23 award)

2001–2004 Maggie Nellissery, M.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center

2000–2006 Amira Pierucci-Lagha, Ph.D., Postdoctoral Fellow, Alcohol Research Center (2000-2003); Instructor (2003-2004); Assistant Professor (2004 – 2006), University of Connecticut School of Medicine

1998–2003 Cheryl Oncken, M.D., Assistant Professor, Department of Medicine, University of Connecticut School of Medicine (Mentor for K23 award)

2000–2001 Jennifer Logan, M.D., Postdoctoral Fellow, Alcohol Research Center, University of Connecticut Health Center

1999–2000 Anjum Ashraf, M.D., Postdoctoral Fellow, Alcohol Research Center, University of Connecticut Health Center

1998–2000 Ola Blomqvist, M.D., Ph.D., Visiting Postdoctoral Fellow, University of Connecticut Health Center

1996–1999 Vania Modesto-Lowe, M.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center

1997–1998 Hetal Amin, M.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center

1996–1998 Carlos Hernandez-Avila, M.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center

1994–1995 Pamela Moore, M.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center

1994–1995 Duk-ki Lee, M.D., Visiting Postdoctoral Fellow, Department of Psychiatry, University of Connecticut Health Center

1994 Rodrigo Escobar, M.D., Visiting Postdoctoral Fellow, Alcohol Research Center, University of Connecticut Health Center

1992–1994	Andrew Apter, Ph.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center
1993	Harriet Ackerman, M.D., Postdoctoral Fellow, Department of Psychiatry, University of Connecticut Health Center
1990–1992	Michael Bohn, M.D., NIAAA Postdoctoral Fellow, University of Connecticut Health Center

THESIS AND DISSERTATION COMMITTEE MEMBERSHIP

2015	Jiangwen Sun: Ph.D. Dissertation in Computer Science, University of Connecticut
2012	Kara Douglas: Ph.D. Dissertation in Clinical Psychology, Drexel University
2010	Kevin Jensen: Ph.D. Dissertation in Biomedical Science, University of Connecticut Health Center
2007	Paul Gacek: M.P.H. Thesis, University of Connecticut
2006	Carlos Hernandez-Avila, M.D.: Ph.D. Dissertation in Biobehavioral Sciences, University of Connecticut
2005	Kristen Tremblay: M.P.H. Thesis, University of Connecticut

JOURNAL EDITORSHIP

Addictive Disorders and Their Treatment (Editorial Board, 2001–2018)
Addiction (Assistant Editor, 1995–2010)
Addiction Biology (Editorial Board, 2012–present)
Alcohol Health and Research World (Editorial Advisory Board, 1994–1996)
Alcohol Research and Health (Editorial Advisory Board, 2006–2008)
Alcoholism: Clinical and Experimental Research (Board of Review Editors, 2007–2014; Editor,
2014–present)
American Journal on Addictions (Editorial Board, 1999–2012; Associate Editor, 2000–2010)
Current Behavioral Neuroscience Reports (Section Editor: Addictions, 2013–2014)
Drug and Alcohol Dependence (Editorial Board, 2004–present)
Experimental and Clinical Psychopharmacology (Editorial Consultant, 2010–2017)
International Journal of Neuropsychopharmacology (Editorial Board, 2014–present)
Neuropsychopharmacology (Editorial Board, 2008–2012)

PUBLICATIONS

Reports in Refereed Journals

1. Babor TF, **Kranzler HR**, Kadden R. Issues in the definition and diagnosis of alcoholism: Implications for a reformulation. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 10:1-20, 1986. (PMID: 3529239)

2. Babor TF, **Kranzler HR**, Lauerman RJ. Social drinking as a health and psychosocial risk factor: Anstie's limit revisited. In Galanter, M. (Ed.). *Recent Developments in Alcoholism* 5:373-402, 1987. (PMID: 3550915)
3. Meyer RE, **Kranzler HR**. Alcoholism: Clinical implications of recent research. *Journal of Clinical Psychiatry* 49 [9, Suppl]:8-12, 1988. (PMID: 3047109)
4. Babor TF, **Kranzler HR**, Lauerman RJ. Early detection of harmful alcohol consumption: Comparison of clinical, laboratory and self-report screening procedures. *Addictive Behaviors* 14:139-157, 1989. (PMID: 2728952)
5. **Kranzler HR**, Babor TF, Lauerman R. Problems associated with average alcohol consumption and frequency of intoxication in a medical population. *Alcoholism: Clinical and Experimental Research* 14:119-126, 1990. (PMID: 2178464)
6. **Kranzler HR**, Dolinsky Z, Kaplan RF. Giving ethanol to alcoholics in a research setting: Its effect on compliance with disulfiram treatment. *British Journal of Addiction* 85:119-123, 1990. (PMID: 2310844)
7. Wong SHY, Dellafera SS, Fernandes R, **Kranzler H**. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. *Journal of Chromatography* 499:601-608, 1990. (PMID: 2324217)
8. **Kranzler HR**, Babor TF, Goldstein L, Gold J. Dental pathology and alcohol-related indicators in an outpatient clinic sample. *Community Dentistry and Oral Epidemiology* 18:204-207, 1990. (PMID: 2387137)
9. El-Mallakh RS, **Kranzler HR**, Kamanitz JR. The association between headaches and alcohol and drug use in substance abuse patients. *Headache Quarterly* 2:319:322, 1991.
10. Gelernter J, O'Malley S, Risch N, **Kranzler H**, Krystal J, Merikangas K, Kennedy J, Kidd K. No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. *JAMA* 266:1801-1807, 1991. (PMID: 1832467)
11. El-Mallakh RS, **Kranzler HR**, Kamanitz JR. Headaches and psychoactive substance use. *Headache* 31:584-587, 1991. (PMID: 1774172)
12. **Kranzler HR**, Manu P, Lane T, Matthews D, Hesselbrock V. Substance use disorders in chronic fatigue patients. *Hospital and Community Psychiatry* 42:924-928, 1991. (PMID: 1743663)
13. Gillen RW, **Kranzler HR**, Kadden RM, Weidenman MA. Utility of a brief cognitive screening instrument in substance abuse patients: Initial investigation. *Journal of Substance Abuse Treatment* 8:247-251, 1991. (PMID: 1664866)
14. **Kranzler HR**, Wallington DJ. Serum prolactin level, craving, and early discharge from treatment in cocaine-dependent patients. *American Journal of Drug and Alcohol Abuse*, 18:187-195, 1992. (PMID: 1314018)
15. Brown J, **Kranzler HR**, Del Boca F. Self-reports by alcohol and drug abuse inpatients: factors affecting reliability and validity. *British Journal of Addiction*, 87:1013-1024, 1992. (PMID: 1322747)

16. **Kranzler HR**, Dellafera SS, McLaughlin LD, Wong SHY. Persistent urinary benzoylecgonine following cocaine use. *American Journal on Addictions*, 1:265-271, 1992.
17. **Kranzler HR**, Bauer LO. Bromocriptine and cocaine cue reactivity in cocaine-dependent patients. *British Journal of Addiction*, 83:1537-1548, 1992. (PMID: 1458033)
18. Rounsaville BJ, Bryant K, Babor TF, **Kranzler H**, Kadden R. Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10. *British Journal of Addiction*, 88:337-348, 1993. (PMID: 8461851)
19. **Kranzler HR**, Del Boca F, Korner P, Brown J. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. *Journal of Substance Abuse Treatment*, 10: 283-287, 1993. (PMID: 8315702)
20. Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum K, Noble EP, **Kranzler HR**, O'Malley S, Hamer DH, Whitsitt F, Rao P, DeLisi LE, Virkkunen M, Linnoila M, Goldman D, Gershon ES. No structural mutation in the dopamine D₂ receptor gene in alcoholism or schizophrenia. *JAMA*, 271:204-208, 1994. (PMID: 8277546)
21. Manu P, Burlison JA, **Kranzler HR**. Patient predictors of irregular discharge from inpatient substance abuse treatment. *American Journal on Addictions*, 3:122-128, 1994.
22. Bohn MJ, **Kranzler HR**, Beazoglou D, Staehler BA. Naltrexone and brief counseling to reduce heavy drinking. *American Journal on Addictions*, 2:91-99, 1994.
23. **Kranzler HR**, Kadden RM, Babor TF, Rounsaville BJ. Longitudinal, Expert, All Data Procedure for psychiatric diagnosis in patients with psychoactive substance use disorders. *Journal of Nervous and Mental Disease*, 182:277-283, 1994. (PMID: 10678309)
24. Bauer LO, **Kranzler HR**. Electroencephalographic activity and mood in cocaine-dependent outpatients: Effects of cocaine cue exposure. *Biological Psychiatry*, 36:189-197, 1994. (PMID: 7948456)
25. **Kranzler HR**, Burlison JA, Del Boca FK, Babor TF, Korner PF, Brown JA, Bohn MJ. Buspirone treatment of anxious alcoholics: A placebo-controlled trial. *Archives of General Psychiatry*, 51:720-731, 1994. (PMID: 8080349)
26. **Kranzler H R**, Satel S, Apter A. Personality disorders and associated features in cocaine-dependent patients. *Comprehensive Psychiatry*, 35:335-340, 1994. (PMID: 7995024)
27. Krystal JH, Webb E, Cooney N, **Kranzler HR**, Charney DS. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. *Archives of General Psychiatry*, 51:898-911, 1994. (PMID: 7944878)
28. Gelernter J, **Kranzler HR**, Satel S, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. *Neuropsychopharmacology*, 11:195-200, 1994. (PMID: 7865100)

29. **Kranzler HR**, Anton RF. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. *Journal of Consulting and Clinical Psychology* 62:1116-1126, 1994. (PMID: 7860810)
30. **Reprinted** in Marlatt, G.R. and G.R. Vandenbos (Eds.): *Addictive Behaviors: Readings on Etiology, Prevention, and Treatment*, Washington, D.C.: American Psychological Association: pp. 68-93, 1997.
31. Wong SHY, **Kranzler HR**, DellaFera S, Fernandes R. Determination of fluvoxamine concentration in plasma by reversed-phase liquid chromatography. *Biomedical Chromatography*, 8:278-282, 1994. (PMID: 7888729)
32. **Kranzler HR**, Bureson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. *American Journal of Psychiatry*, 152:391-397, 1995. (PMID: 7864265)
33. Anton RF, **Kranzler HR**, Meyer RE. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. In Meyer RE, Kranzler HR (Eds.), *Clinical Neuroscience: Alcoholism*, 3:145-154, 1995. (PMID: 8612059)
34. Kadden RM, **Kranzler HR**, Rounsaville BJ. Validity of the distinction between "substance-induced" and "independent" depression and anxiety disorders. *American Journal on Addictions*, 4:107-117, 1995.
35. Bohn MJ, Babor TF, **Kranzler HR**. The Alcohol Use Disorders Identification Test (AUDIT): Validation of a screening instrument for use in medical settings. *Journal of Studies on Alcohol*, 56:423-432, 1995. (PMID: 7674678)
36. **Kranzler HR**, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: A placebo-controlled trial. *Drug and Alcohol Dependence*, 38: 203-211, 1995. (PMID: 7555620)
37. **Kranzler HR**, Kadden RM, Bureson JA, Babor TF, Apter A, Rounsaville BJ. The validity of psychiatric diagnoses in patients with substance use disorders: Is the interview more important than the interviewer? *Comprehensive Psychiatry*, 36:278-288, 1995. (PMID: 7555620)
38. Hersh D, Bauer LO, **Kranzler HR**. Carbamazepine and cocaine-cue reactivity. *Drug and Alcohol Dependence*, 39:213-221, 1995. (PMID: 8556970)
39. **Kranzler HR**, Stone J, McLaughlin L. Evaluation of a point-of-care testing product for drugs of abuse: Operator dependence is a key variable. *Drug and Alcohol Dependence*, 40:55-62, 1995. (PMID: 8746925)
40. Krystal JH, Webb E, Cooney NL, **Kranzler HR**, Southwick SW, Heninger GR, Charney DS. Serotonergic and noradrenergic dysregulation in alcoholism: *m*-CPP and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. *American Journal of Psychiatry*, 153:83-92, 1996. (PMID: 8540598)
41. **Kranzler HR**, Escobar R, Lee DK, Meza E. Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. *Alcoholism: Clinical and Experimental Research*, 20:16-20, 1996. (PMID: 8651447)

42. **Kranzler HR**, Kadden RM, Babor TF, Tennen H, Rounsaville, BJ. Validity of the SCID in substance abuse patients. *Addiction*, 91:859-868, 1996. (PMID: 8696248)
43. Feingold A, Ball SA, **Kranzler HR**, Rounsaville BJ. Generalizability of the Type A/Type B distinction across different psychoactive substances. *American Journal of Drug and Alcohol Abuse*, 22:449-462, 1996. (PMID: 8841691)
44. Freimer M, **Kranzler HR**, Satel S, Lacobelle J, Skipsey K, Gelernter J. No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. *Addiction Biology*, 1:281-287, 1996. (PMID: 12893467)
45. **Kranzler HR**, Del Boca FK, Rounsaville BJ. Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: A post-treatment natural history study. *Journal of Studies on Alcohol*, 57:619-626, 1996. (PMID: 8913993)
46. **Kranzler HR**, Moore PJ, Hesselbrock VM. No association of PROP taster status and family history of alcoholism. *Alcoholism: Clinical and Experimental Research*, 20:1496-1500, 1996. (PMID: 8947330)
47. Del Boca FK, **Kranzler HR**, Brown J, Korner P. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. *Alcoholism: Clinical and Experimental Research*, 20:1412-1417, 1996. (PMID: 8947318)
48. **Kranzler HR**, Burlison JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in Type B alcoholics. *Alcoholism: Clinical and Experimental Research*, 20:1534-1541, 1996. (PMID: 8986200)
49. Johnson BA, Jasinski DR, Galloway GP, **Kranzler HR**, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C. Ritanserin in the treatment of alcohol dependence - a multi-center trial. *Psychopharmacology (Berl)*, 128:206-215, 1996. (PMID: 8956382)
50. **Kranzler HR**, McCaul ME, Gelernter J, Wand GS. No allelic association of an exon 13 polymorphism of the $G_s\alpha$ gene with alcohol or drug dependence. *Addiction Biology*, 3:309-315, 1997.

51. **Kranzler HR**, Tennen H, Penta C, Bohn M. Targeted naltrexone treatment in early problem drinkers. *Addictive Behaviors*, 22:431-436, 1997. (PMID: 9183513)
52. Skipsey K, Bureson JR, **Kranzler HR**. Utility of the AUDIT for identification of alcohol use disorders in drug abusers. *Drug and Alcohol Dependence*, 45:157-163, 1997. (PMID: 9179517)
53. Cubells JF, Kobayashi K, Nagatsu T, Kidd KK, Kidd JR, **Kranzler H**, Ichinose H, Gelernter J. Population genetics of a functional variant of the dopamine β -hydroxylase gene (DBH). *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 74B374-379, 1997. (PMID: 9259372)
54. Anton RF, **Kranzler HR**, McEvoy JP, Moak DH, Bianca R. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. *Psychopharmacology (Berl)*, 131:123-129, 1997. (PMID: 9201799)
55. **Kranzler HR**, Tennen H, Babor TF, Kadden RM, Rounsaville BJ. Validity of the Longitudinal, Expert, All Data procedure for psychiatric diagnosis in patients with psychoactive substance use disorders. *Drug and Alcohol Dependence*, 45:93-104, 1997. (PMID: 9179511)
56. Gelernter J, **Kranzler H**, Cubells JF. Serotonin transporter protein (*SLC6A4*) allele and haplotype frequencies in three populations (African and European American and Japanese) and in alcohol-dependent subjects. *Human Genetics*, 101:243-246, 1997. (PMID: 9402979)
57. Ball SA, Tennen H, Poling JC, **Kranzler HR**, Rounsaville BJ. Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers. *Journal of Abnormal Psychology*, 106:545-553, 1997. (PMID: 9358685)
58. Gelernter J, **Kranzler H**, Coccaro E, Siever L, New A, Mulgrew CL. D4 dopamine-receptor (DRD4) alleles and novelty seeking in substance-dependent, personality-disorder, and control subjects. *American Journal of Human Genetics*, 61:1144-1152, 1997. (PMID: 9345090; PMCID: PMC1716050)
59. Modesto-Lowe V, Bureson JA, Hersh D, Bauer LO, **Kranzler HR**. Effects of naltrexone on cue-elicited craving for alcohol and cocaine. *Drug and Alcohol Dependence*, 49:9-16, 1997. (PMID: 9476694)
60. Rounsaville BJ, **Kranzler HR**, Ball S, Tennen H, Poling J, Triffleman E. Personality disorders in substance abusers: Relation to substance use. *Journal of Nervous and Mental Disease*, 186:87-95, 1998. (PMID: 9484308)
61. Ball SA, **Kranzler HR**, Tennen H, Poling JC, Rounsaville BJ. Personality disorder and dimension differences between Type A and Type B substance abusers. *Journal of Personality Disorders*, 12:1-12, 1998. (PMID: 9573515)
62. Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, **Kranzler HR**. Carbamazepine versus haloperidol treatment of inhalant-induced psychotic disorder. *Psychiatric Services*, 49:812-815, 1998. (PMID: 9634163)

63. Carney MA, Tennen H, Affleck G, Del Boca FK, **Kranzler HR**. Levels and patterns of alcohol consumption using timeline follow-back, daily diaries, and real-time “electronic interviews.” *Journal of Studies on Alcohol*, 59:447-454, 1998. (PMID: 9647427)
64. Gelernter J, **Kranzler H**, Cubells JF, Ichinose H, Nagatsu T. DRD2 allele frequencies and linkage disequilibria including the -141CIns/Del promoter polymorphism, in European-American, African-American, and Japanese Subjects, *Genomics* 51:21-26, 1998. (PMID: 9693029)
65. **Kranzler HR**, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: A preliminary study. *Alcoholism: Clinical and Experimental Research*, 22:1074-1079, 1998. (PMID: 9726277)
66. **Kranzler HR**, Gelernter J, O’Malley S, Hernandez CA, Kaufman D. Association of alcohol or other drug dependence with alleles of the μ opioid receptor gene (*OPRM1*), *Alcoholism: Clinical and Experimental Research*, 22:1359-1362, 1998. (PMID: 9756053)
67. Gelernter J, **Kranzler H**, Coccaro E, Siever L, New A. Serotonin transporter protein polymorphism and personality measures in African and European American subjects. *American Journal of Psychiatry* 155:1332-1338, 1998. (PMID: 9766763)
68. **Kranzler HR**, Skipsey K, Modesto-Lowe V. PROP taster status and parental history of alcohol dependence. *Drug and Alcohol Dependence*, 52:109-113, 1998. (PMID: 9800140)
69. Hersh D, Van Kirk JR, **Kranzler HR**. Naltrexone treatment of comorbid alcohol and cocaine use disorders. *Psychopharmacology (Berl)*, 139:44-52, 1998. (PMID: 9768541)
70. Gillen RW, **Kranzler HR**, Bauer LO, Burleson JA, Samarel D, Morrison DJ. Neuropsychologic findings in cocaine-dependent outpatients. *Progress in Neuro-psychopharmacology and Biological Psychiatry*, 22:1061-1076, 1998. (PMID: 9829288)
71. Feng J, Sobell JL, Heston LL, Goldman D, Cook E Jr, **Kranzler HR**, Gelernter J, Sommers SS. Variants in the α_{2A} adrenergic receptor gene in psychiatric patients. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 81B:405-410, 1998. (PMID: 9754626)
72. Gelernter J, **Kranzler H**, Lacobelle J. Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), μ opioid receptor (*OPRM1*), and ciliary neurotrophic factor (*CNTF*). *Genomics*, 52:289-297, 1998. (PMID: 9790747)
73. Hernandez-Avila CA, Burleson JA, **Kranzler HR**. Stage of change as a predictor of abstinence among alcohol-dependent subjects in pharmacotherapy trials. *Substance Abuse*, 19:81-91, 1998. (PMID: 12511809)

74. **Kranzler HR**, Mulgrew CL, Modesto-Lowe V, Burleson JA. Validity of the Obsessive-Compulsive Drinking Scale (OCDS): Does craving predict drinking behavior? *Alcoholism: Clinical and Experimental Research*, 23:108-114, 1999. (PMID: 10029210)
75. Hersh D, Mulgrew CL, Van Kirk J, **Kranzler HR**. The validity of self-reported cocaine use in two groups of cocaine abusers. *Journal of Consulting and Clinical Psychology*, 67:37-42, 1999. (PMID: 10028207)
76. Gelernter J, **Kranzler H**, Satel S. No association between D₂ dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. *Biological Psychiatry*, 45:340-345, 1999. (PMID: 10023512)
77. Gelernter J, **Kranzler HR**. D₂ dopamine receptor gene (DRD2) allele and haplotype frequencies in alcohol dependent and control subjects: No association with phenotype or severity of phenotype. *Neuropsychopharmacology*, 20:640-649, 1999. (PMID: 10327432)
78. Cecero JJ, Ball SA, Tennen H, **Kranzler HR**, Rounsaville BJ. Concurrent and predictive validity of antisocial personality disorder subtyping among substance abusers. *Journal of Nervous and Mental Disease*, 187:478-486, 1999. (PMID: 10463065)
79. Gelernter J, **Kranzler H**, Cubells J. Genetics of two μ receptor gene (*OPRM1*) exon I polymorphisms: Population studies, and allele frequencies in alcohol and drug dependent subjects. *Molecular Psychiatry*, 4:476-483, 1999. (PMID: 10523821)
80. Modesto-Lowe V, **Kranzler HR**. Using cue reactivity to evaluate medications for cocaine dependence treatment: A critical review. *Addiction*, 94:1639-1651, 1999. (PMID: 10892004)
81. Ball SA, Tennen H, **Kranzler HR**. Factor replicability and validity of the Temperament and Character Inventory in substance-dependent patients. *Psychological Assessment*, 11:514-524, 1999.
82. Poling J, Rounsaville BJ, Ball S, Tennen H, **Kranzler HR**, Triffleman E. Rates of personality disorders in substance abusers: A comparison between DSM-III-R and DSM-IV. *Journal of Personality Disorders*, 13:375-384, 1999. (PMID: 10633317)
83. Verheul R, **Kranzler HR**, Poling J, Tennen H, Ball S, Rounsaville BJ. Axis I and axis II disorders in alcoholics and drug addicts: Fact or artifact. *Journal of Studies on Alcohol*, 61:101-110, 2000. (PMID: 10627103)
84. Cubells JF, **Kranzler HR**, McCance-Katz E, Anderson GM, Malison RT, Price LH, Gelernter J. A haplotype at the DBH locus, associated with low plasma dopamine β -hydroxylase activity, also associates with cocaine-induced paranoia. *Molecular Psychiatry* 5:56-63, 2000. (PMID: 10673769)
85. Petry NM, Martin B, Cooney JL, **Kranzler HR**. Give them prizes and they will come: Variable-ratio contingency management for treatment of alcohol dependence. *Journal of Consulting and Clinical Psychology*, 68:250-257, 2000. PMID: 10780125

86. **Kranzler HR**, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence: A placebo-controlled trial. *Neuropsychopharmacology*, 22:493-503, 2000. (PMID: 10731624)
87. Verheul R, **Kranzler HR**, Poling J, Tennen H, Ball S, Rounsaville BJ. Co-occurrence of Axis I and Axis II disorders in substance abusers. *Acta Psychiatrica Scandinavica*, 101:110-118, 2000. (PMID: 10706010)
88. Hernandez-Avila CA, Burleson JA, Poling J, Tennen H, Rounsaville BJ, **Kranzler HR**. Personality and substance use disorders as predictors of criminality. *Comprehensive Psychiatry*, 41:276-283, 2000. (PMID: 10929796)
89. Pettinati HM, Volpicelli JR, **Kranzler HR**, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: Interactive effects of medication and subtype. *Alcoholism: Clinical and Experimental Research*, 24:1041-1049, 2000. (PMID: 10924008)
90. Gelernter J, **Kranzler HR**. Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. *Human Genetics*, 107:86-88, 2000. (PMID: 10982041)
91. Blomqvist O, Gelernter J, **Kranzler HR**. A family-based study of DRD2 alleles in alcohol and drug dependence. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 96B:659-664, 2000. (PMID: 11054774)
92. Armeli S, Tennen H, **Kranzler HR**. Does affect mediate the association between daily events and alcohol use? *Journal of Studies on Alcohol*, 61:862-871, 2000. (PMID: 11188492)
93. Pettinati HM, Volpicelli JR, Luck G, **Kranzler HR**, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. *Journal of Clinical Psychopharmacology*, 21:143-153, 2001. (PMID: 11270910)
94. Feng J, Zheng J, Gelernter J, **Kranzler H**, Cook E, Goldman D, Jones IR, Craddock N, Heston LL, Delisi L, Peltonen L, Bennett WP, Sommer SS. An in-frame deletion in the alpha(2C) adrenergic receptor is common in African-Americans. *Molecular Psychiatry*, 6:168-172, 2001. (PMID: 11317218)
95. **Kranzler HR**, Sandstrom KA, Van Kirk J. Sweet taste preference as a risk factor for alcohol dependence. *American Journal of Psychiatry*, 158:813-815, 2001. (PMID: 11329410)
96. Ball SA, Rounsaville BJ, Tennen H, **Kranzler HR**. Reliability of personality disorder symptoms and personality traits in substance-dependent inpatients. *Journal of Abnormal Psychology*, 110:341-52, 2001. (PMID: 11358028)
97. Oncken C, Van Kirk J, **Kranzler HR**. Adverse effects of oral naltrexone: Analysis of data from two clinical trials. *Psychopharmacology (Berl)*, 154:397-402, 2001. (PMID: 11349393)

98. Covault J, Gelernter J, **Kranzler H**. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. *Molecular Psychiatry*, 6:501-502, 2001. (PMID: 11526463)
99. **Kranzler HR**, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. *Alcoholism: Clinical and Experimental Research*, 25:1335-1341, 2001. (PMID: 11584154)
100. Anton RF, Dominick C, Bigelow M, Westby C. and the CDTeCt Research Group (Doot M, **Kranzler H**, Miller B, O'Brien C, Pettinati H, Ramirez L, Swift R, Zweben A). Comparison of Bio-Rad %CDT TIA and CDTeCt as laboratory markers of heavy alcohol use and their relationships with γ -glutamyltransferase. *Clinical Chemistry* 47:1769-1775, 2001. (PMID: 11568085)
101. **Kranzler HR**, Hernandez-Avila C, Gelernter J. Polymorphism of the 5-HT1B receptor gene (*HTR1B*) and antisocial substance dependence. *Neuropsychopharmacology*, 26:115-122, 2002. PMID: 11751038
102. Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE, **Kranzler HR**. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. *Alcoholism: Clinical and Experimental Research*, 26:326-331, 2002. (PMID: 11923584)
103. Petry NM, Kirby KN, **Kranzler HR**. Effects of gender and paternal history of alcoholism on discount rates for delayed rewards in healthy subjects. *Journal of Studies on Alcohol* 63:83-90, 2002. (PMID: 11925063)
104. Hernandez-Avila CA, Oncken C, Van Kirk J, Wand G, **Kranzler HR**. Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism. *Biological Psychiatry* 51:652-658, 2002. (PMID: 11955465)
105. Oncken CA, **Kranzler HR**, O'Malley P, Gendreau P, Campbell WA. The effect of cigarette smoking on fetal heart rate characteristics. *Obstetrics and Gynecology*, 99:751-755, 2002. (PMID: 11978283)
106. Anton RF, Lieber C, Tabakoff B. for the CDTeCt Study Group (Doot M, **Kranzler H**, Lieber C, Miller B, O'Brien C, Pettinati H, Ramirez L, Swift R, Tabakoff B, Zweben A). CDT and GGT for the detection and monitoring of alcohol use: Results from a multisite study. *Alcoholism: Clinical and Experimental Research*, 26:1215-1222, 2002. (PMID: 12198396)
107. **Kranzler HR**, Amin H, Cooney NL, Cooney JL, Burleson JA, Petry N, Oncken CA. Screening for health behaviors in ambulatory clinical settings: Does smoking status predict hazardous drinking? *Addictive Behaviors*, 27:737-749, 2002. (PMID: 12201381)
108. Lappalainen J, **Kranzler HR**, Malison R, Price LH, Van Dyck C, Rosenheck RA, Cramer J, Southwick S, Charney D, Krystal J, Gelernter J. A functional neuropeptide Y Leu7Pro polymorphism is associated with alcohol dependence in a large population sample from the U.S. *Archives of General Psychiatry*, 59:825-831, 2002. (PMID: 12215082)

109. **Kranzler HR**, Lappalainen J, Nellissery M, Gelernter J. Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. *Alcoholism: Clinical and Experimental Research*, 26:1330-1335, 2002. (PMID: 12351926)
110. Oncken CA, Henry KM, Campbell WA, Kuhn CM, Slotkin TA, **Kranzler HR**. Effect of maternal smoking on fetal catecholamine concentrations at birth. *Pediatric Research*, 53:119-124, 2003. (PMID: 12508090)
111. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, **Kranzler HR**. Association between the cortisol response to opioid blockade and alleles of the Asn40Asp polymorphism at the μ -opioid receptor locus (*OPRM1*). *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 118B:60-65, 2003. (PMID: 12627468)
112. Mark TL, **Kranzler HR**, Song X, Bransberger P, Poole V, Crosse S. Physicians' opinions about medications to treat alcoholism. *Addiction*, 98:617-626, 2003. (PMID: 12751979)
113. Cooney JL, Cooney NL, Pilkey D, **Kranzler HR**, Oncken CA. Effect of nicotine deprivation on urges to drink and smoke in alcoholic smokers. *Addiction*, 98:913-921, 2003. (PMID: 12814497)
114. Sandstrom KA, Rajan TM, Feinn R, **Kranzler HR**. Salty and sour taste characteristics and risk of alcoholism. *Alcoholism: Clinical and Experimental Research*, 27:955-961, 2003. (PMID: 12824816)
115. **Kranzler HR**, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R. Targeted naltrexone for early problem drinkers. *Journal of Clinical Psychopharmacology*, 23:294-304, 2003.
116. Luo X, **Kranzler HR**, Zhao H, Gelernter J. Haplotypes at the *OPRM1* locus are associated with susceptibility to substance dependence in European-Americans. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 120B:97-108, 2003. PMID: 12815747
117. **Kranzler HR**, Pierucci-Lagha A, Feinn R, Hernandez-Avila C. Effects of ondansetron in early- vs. late-onset alcoholics: A prospective, open-label study. *Alcoholism: Clinical and Experimental Research*, 27:1150-1155, 2003. PMID: 12878921
118. Oslin DW, Berrettini W, **Kranzler HR**, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A functional polymorphism of the μ -opioid receptor gene is associated with response to naltrexone treatment in alcohol-dependent patients. *Neuropsychopharmacology*, 28:1546-1552, 2003.
119. Feinn R, Tennen T, Cramer J, **Kranzler HR**. Measurement and prediction of medication compliance in alcoholics. *Alcoholism: Clinical and Experimental Research*, 27:1286-1292, 2003. PMID: 12966323
120. Mark TL, **Kranzler HR**, Song X. Understanding U.S. addiction physicians' low rate of naltrexone prescription. *Drug and Alcohol Dependence* 219-228, 2003. PMID: 12957340

121. Covault J, Abreu C, **Kranzler HR**, Oncken C. Quantitative real-time PCR for gene dosage determinations in microdeletion genotypes. *BioTechniques* 35:594-598, 2003. PMID: 14513564
122. Nellissery M, Feinn RS, Covault J, Gelernter J, Anton RF, Pettinati H, Moak D, Mueller T, **Kranzler HR**. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. *Alcoholism: Clinical and Experimental Research* 27:1402-1408, 2003. PMID: 14506400
123. Pettinati HM, **Kranzler HR**, Madaras J. The status of serotonin-selective pharmacotherapy in the treatment of alcohol dependence. Galanter, M. (Ed.), *Recent Developments in Alcoholism*, New York: Plenum Press, 16:247-62, 2003. (PMID: 12638641)
124. Feinn R, Tennen H, **Kranzler HR**. Psychometric properties of the SIP in measuring recent alcohol-related problems. *Alcoholism: Clinical and Experimental Research*, 27:1436-1441, 2003. PMID: 14506404
125. Mark T, **Kranzler HR**, Poole VH, Hagen CA, McLeod C, Crosse SE. Barriers to the use of medications to treat alcoholism. *American Journal on Addictions*, 12:281-294, 2003. PMID: 14504021
126. Zabetian CP, Romero R, Robertson D, Sharma, S, Padbury JF, Kuivaniemi H, Kim KS, Kim CH, Kohnke MD, **Kranzler HR**, Gelernter J, Cubells JF. A revised allele frequency estimate and haplotype analysis of the DBH deficiency mutation IVS1+2T --> C in African- and European-Americans. *American Journal of Medical Genetics* 123A:190-192, 2003. PMID: 14598346
127. Blomqvist O, Hernandez-Avila CA, Bureson JA, Ashraf A, **Kranzler HR**. Self-efficacy as a predictor of relapse during treatment for alcohol dependence. *Addictive Disorders and Their Treatment* 2:135-145, 2003.
128. Lappalainen J, Sanacora G, **Kranzler HR**, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 124B:81-86, 2004. PMID: 14681921
129. Littleton JM, de Witte P, Litten R, Gessa, GL, Spanagel R, **Kranzler H**, Lehert P, Johnson B, Saunders J, Berglund M, Harris A, Anton R, Mann K. Challenges to medications development in treating alcohol dependence: an international perspective. *Alcohol and Alcoholism*, 39:271-275, 2004. (PMID: 15208155)
130. Luo X, Klempan T, Lappalainen J, Rosenheck R, Charney D, Erdos J, van Kammen DP, **Kranzler HR**, Kennedy J, Gelernter J. NOTCH4 gene haplotypes are associated with schizophrenia in African-Americans. *Biological Psychiatry* 55:112-117, 2004. PMID: 14732589
131. Pierucci-Lagha A, Feinn R, Modesto-Lowe V, Swift R, Nellissery M, Covault J, **Kranzler HR**. Effects of rapid tryptophan depletion on mood and urge to drink among patients with co-morbid major depression and alcohol dependence. *Psychopharmacology (Berl)* 171:340-348, 2004.

132. Luo X, **Kranzler H**, Lappalainen J, Rosenheck R, Charney D, Zuo L, Erdos J, van Kammen DP, Gelernter J. CALCYON gene variation, schizophrenia and cocaine dependence. *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 125B:25-30, 2004. PMID: 14755439
133. Lappalainen L, **Kranzler HR**, Petrakis I, Somberg LK, Page G, Krystal J, Gelernter J. Confirmation and fine-mapping of the chromosome 1 alcohol dependence risk locus. *Molecular Psychiatry* 9: 312-319, 2004. PMID: 15094791
134. Basu D, Ball S, Feinn R, Rounsaville B, Gelernter J, **Kranzler HR**. Typologies of drug dependence: The comparative validity of a multivariate and four univariate models. *Drug and Alcohol Dependence* 73:289-300, 2004. PMID: 15036551
135. Hernandez-Avila CA, Modesto-Lowe V, Feinn R., **Kranzler HR**. Nefazodone treatment of comorbid alcohol dependence and major depression. *Alcoholism: Clinical and Experimental Research*, 28:433-440, 2004. PMID: 15084901
136. **Kranzler HR**, Armeli S, Feinn R, Tennen H. Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers. *Journal of Consulting and Clinical Psychology* 72:317-327, 2004.
137. Covault J, Pettinati H, Moak D, Mueller T, **Kranzler HR**. Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 127B:42-47, 2004. PMID: 15108178
138. Hernandez-Avila CA, Covault J, Gelernter J, **Kranzler HR**. Association study of personality factors and the Asn40Asp polymorphism at the μ -opioid receptor gene (*OPRM1*). *Psychiatric Genetics*, 14:89-92, 2004. PMID: 15167694
139. Hernandez-Avila CA, Rounsaville BJ, **Kranzler HR**. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. *Drug and Alcohol Dependence*, 74:265-272, 2004. PMID: 15194204
140. Covault J, Lee J, Jensen K, **Kranzler HR**. NOGO 3'-untranslated region CAA insertion and schizophrenia: Failure to replicate association. *Brain Research. Molecular Brain Research*, 120:197-200, 2004. PMID: 14741411
141. Anton RF, Pettinati H, Zweben A, **Kranzler HR**, Johnson B, Bohn M, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. *Journal of Clinical Psychopharmacology*, 24:421-428, 2004. PMID: 15232334
142. **Kranzler HR**, Wesson DR, Billot L, DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: A multi-center, randomized, placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research*, 28:1051-1059, 2004.
143. Covault C, Gelernter J, Hesselbrock V, Nellissery M, **Kranzler HR**: Allelic and haplotypic association of *GABRA2* with alcohol dependence, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 129B:104-109, 2004.

144. Feinn R, Nellissery M, **Kranzler HR**. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism and alcohol dependence. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 133B:79-84, 2005. (PMID: 15635638)
145. Garbutt JC **Kranzler HR**, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW for the Vivitrex® Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. *JAMA*, 293:1617-1625, 2005.
146. Todd M, Armeli S, Tennen H, Carney MA, Ball SA, **Kranzler HR**, Affleck G: Drinking to cope: A comparison of questionnaire and electronic diary reports. *Journal of Studies on Alcohol*, 66:121-129, 2005. (PMID: 15830912)
147. Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, Zvartau E, Somberg LK, Covault J, **Kranzler HR**, Krystal J, Gelernter J. Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. *Alcoholism: Clinical and Experimental Research*, 29:493-498, 2005. (PMID: 15834213)
148. Yang BZ, Zhao H, **Kranzler HR**, Gelernter J. Practical population group assignment with selected informative markers: Characteristics and properties of Bayesian clustering via STRUCTURE. *Genetic Epidemiology*, 28:302-312, 2005. (PMID: 15782414)
149. Pierucci-Lagha A, Covault J, Feinn R, Nellissery M, Hernandez-Avila C, Oncken C, Morrow AL, **Kranzler HR**. *GABRA2* alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. *Neuropsychopharmacology*, 30:1193-1203, 2005.
150. Feinn R, **Kranzler HR**. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? *Alcoholism: Clinical and Experimental Research*, 29:983-988, 2005. (PMID: 15976524)
151. Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville BJ, Poling J, Wilcox M, Farrer L, **Kranzler HR**. Genomewide linkage scan for cocaine dependence and related traits: Significant linkages for a cocaine-related trait and for cocaine-induced paranoia. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 136B:45-52, 2005. (PMID: 15909294)
152. Luo X, **Kranzler HR**, Zuo L, Blumburg H, Wang S, Gelernter J. *CHRM2* gene predisposes to alcohol dependence, drug dependence, and affective disorders: results from extended case-control structured association studies. *Human Molecular Genetics*, 14:2421-2434, 2005. (PMID: 16000316)
153. Cubells JF, Pearson D, Burda J, Feinn R, Tang Y, Farrer, LA, Gelernter J, **Kranzler HR**. Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). *Drug and Alcohol Dependence*, 80:23-33, 2005. (PMID: 15894433)

154. Luo X, **Kranzler HR**, Zuo L, Yang BZ, Lappalainen J, Gelernter J. *ADH4* gene variation is associated with alcohol and drug dependence: results from family controlled and population-structured association studies. *Pharmacogenetics and Genomics*, 15:755-768, 2005. (PMID: 16220108)
155. Yang BZ, Zhao H, **Kranzler HR**, Gelernter J: Characterization of a likelihood based method and effects of markers informativeness in evaluation of admixture and population group assignment. *BMC Genetics*, 6:50, 2005 (PMCID: PMC1285360)
156. Pierucci-Lagha A, Gelernter J, Feinn R, Cubells J, Pearson D, Farrer L, **Kranzler HR**. Diagnostic reliability of the Semi-structured Assessment of Drug Dependence and Alcoholism (SSADDA). *Drug and Alcohol Dependence*, 80: 303-312, 2005. (PMID: 15896927)
157. Pollastri AR, Pokrywa ML, Walsh SJ, **Kranzler HR**, Gelernter J. Incentive program decreases no-shows and increases responsible cancellation in non-treatment substance abuse research. *Clinical and Experimental Psychopharmacology*, 13:376-380, 2005. (PMID: 16366768)
158. Edenberg HJ, **Kranzler HR**: The contribution of genetics to addiction therapy approaches. *Pharmacology and Therapeutics*, 108:86-93, 2005. (PMID: 16026844)
159. **Kranzler HR**, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M: Sertraline treatment of co-occurring alcohol dependence and major depression. *Journal of Clinical Psychopharmacology*, 26:13-20, 2006.
160. Zhang H, **Kranzler HR**, Lappalainen J, Luo X, Yang BZ, Krupitsky E, Pchelina S, Zvartau E, Gelernter J: Association between two μ -opioid receptor gene (*OPRM1*) haplotype blocks and drug or alcohol dependence. *Human Molecular Genetics*, 15:807-819, 2006. (PMID: 16476706)
161. Luo X, **Kranzler HR**, Zuo L, Lappalainen J, Yang B, Gelernter J. *ADH4* gene variation is associated with alcohol dependence and drug dependence in European Americans: Results from HWD tests and case-control association studies. *Neuropsychopharmacology*, 31:1085-1095, 2006. (PMID: 16237392)
162. Zuo L, van Dyck CH, Luo X, **Kranzler HR**, Yang B, Gelernter J: Variation at *APOE* and *STH* loci and Alzheimer's disease. *Behavioral and Brain Functions*, 2:13, 2006 (PMID: 16603077; PMCID: PMC1526745)
163. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, **Kranzler HR**: Targeted vs. daily naltrexone: Secondary analysis of effects on average daily drinking. *Alcoholism: Clinical and Experimental Research*, 30:860-865, 2006. (PMID: 16634855)
164. Gelernter J, Panhuysen C, Wilcox M, Hesselbrock V, Rounsaville B, Poling J, Weiss R, Sonne S, Farrer L, **Kranzler HR**: Genomewide linkage scan for opioid dependence and related traits. *American Journal of Human Genetics*, 78:759-769, 2006. (PMCID: PMC1474044)

165. Luo X, **Kranzler HR**, Zuo L, Wang S, Schork NJ, Gelernter J: Diplotype trend regression analysis of the *ADH* gene cluster and *ALDH2* gene: Multiple significant associations with alcohol dependence. *American Journal of Human Genetics*, 78:973-987, 2006. (PMID: 16685648; PMCID: PMC1474098)
166. Pierucci-Lagha A, Covault, Feinn R, Khisti R, Morrow AL, Marx C, Shampine L, **Kranzler HR**: Subjective effects and changes in steroid hormone concentrations in humans following acute consumption of alcohol. *Psychopharmacology*, 186:451-461, 2006. (PMID: 16341848)
167. Zhang H, Ozbay F, Lappalainen L, **Kranzler HR**, van Dyck CH, Charney DS, Rosenheck R, Price LH, Southwick S, Yang BZ, Rasmussen A, Gelernter J: Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's Disease, affective disorders, posttraumatic stress disorder, schizophrenia and substance dependence. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 141B:387-393, 2006. (PMID: 16649215; PMCID: PMC2567822)
168. Dahl JP, Cubells JF, Ray R, Weller AE, Lohoff FW, Ferraro TN, Oslin DW, Kampman KM, Tang Y, Gelernter J, **Kranzler HR**, O'Brien CP, Berrettini WH: Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence. *Addiction Biology*, 11:76-83, 2006. (PMID: 16759340)
169. Armeli S, Feinn R, Tennen H, **Kranzler HR**: The effects of naltrexone on alcohol consumption and affect reactivity to daily interpersonal events. *Experimental and Clinical Psychopharmacology*, 14:199-208, 2006. (PMID: 16756424)
170. Herman AI, **Kranzler HR**, Cubells JF, Gelernter J, Covault J: Association study of the *CNR1* gene exon 3 alternative promoter region polymorphisms and substance dependence. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 141B:499-503, 2006. (PMID: 16741937; PMCID: PMC2574012)
171. Arias A, Feinn R, **Kranzler HR**: Association of an Asn40Asp (A118G) polymorphism in the μ -opioid receptor gene with substance dependence: A meta-analysis. *Drug and Alcohol Dependence*, 83:262-268, 2006. (PMID: 16387451)
172. Yu Y, Panhuysen C, **Kranzler HR**, Hesselbrock V, Rounsaville B, Weiss R, Brady K, Farrer LA, Gelernter J: Intronic variants in the DOPA decarboxylase (*DDC*) gene are associated with smoking behavior in European-Americans and African-Americans. *Human Molecular Genetics*, 15:2192-2199, 2006. (PMID: 16740595)
173. Kalayasiri R, **Kranzler HR**, Weiss R, Brady K, Gueorguieva R, Panhuysen C, Yang BZ, Farrer L, Gelernter J, Malison RT: Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. *Drug and Alcohol Dependence*, 84:77-84, 2006. (PMID: 16413147)
174. Malison RT, **Kranzler HR**, Yang B, Gelernter J: Human CLOCK, PER1 and PER2 polymorphisms: lack of association with cocaine dependence susceptibility and cocaine-induced paranoia. *Psychiatric Genetics*, 16:245-249, 2006. (PMID: 17106427)

175. Gelernter J, Yu Y, Weiss R, Brady K, Panhuysen C, Yang B, **Kranzler HR**, Farrer L: Haplotype spanning *TTC12* and *ANKK1*, adjacent to the *DRD2* locus, is strongly associated to nicotine dependence in two distinct American populations. *Human Molecular Genetics*, 15:3498-3507, 2006. (PMID: 17085484)
176. Oncken C, Cooney J, Feinn R, Lando H, **Kranzler HR**: Transdermal nicotine for smoking cessation in postmenopausal women. *Addictive Behaviors*, 32:296-309, 2007. (PMID: 16765526)
177. Gelernter J, Panhuysen C, Weiss R, Brady K, Poling J, Krauthammer M, Farrer L, **Kranzler HR**: Genomewide linkage scan for nicotine dependence: Identification of a novel chromosome 5 risk locus. *Biological Psychiatry*, 61:119-26, 2007. (PMID: 16765526)
178. Cohen E, Feinn R, Arias A, **Kranzler HR**: Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug and Alcohol Dependence*, 86:214-221, 2007.
179. Luo X, **Kranzler HR**, Zuo L, Wang S, Schork NJ, Gelernter J: Multiple *ADH* genes modulate risk for drug dependence in both African- and European-Americans. *Human Molecular Genetics*, 16:380-390, 2007. (PMID: 17185388; PMCID: PMC1853246)
180. Luo X, **Kranzler HR**, Zuo L, Wang S, Gelernter J: Personality traits of agreeableness and extraversion are associated with *ADH4* variation. *Biological Psychiatry*, 61:599-608, 2007. (PMID: 17069770; PMCID: PMC1853245)
181. Covault J, Tennen H, Herman AI, Armeli S, Conner T, Cillessen AHN, **Kranzler HR**: Interactive effects of the serotonin transporter 5-HTTLPR polymorphism and stressful life events on college student drinking and drug use. *Biological Psychiatry*, 61:609-616, 2007.
182. Gelernter J, Gueorguieva R, **Kranzler HR**, Zhang H, Cramer J, Rosenheck R, Krystal JH, VA Cooperative Study #425 Study Group: Opioid receptor gene (*OPRM1*, *OPRK1*, and *OPRD1*) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study. *Alcoholism: Clinical and Experimental Research*, 31:555-563, 2007. (PMID: 17374034)
183. Ball SA, Todd M, Tennen H, Armeli S, Mohr C, Affleck G, **Kranzler HR**: Brief motivational enhancement and coping skills interventions for heavy drinking. *Addictive Behaviors*, 32: 1105-1118, 2007. (PMID: 16945487)
184. Listman JB, Malison RT, Sughondhabiroom A, Yang B, Raaum RL, Thavichachart N, **Kranzler HR**, Tangwonchai S, Mutirangura A, Disotell TR, Gelernter J: Demographic changes and marker properties affect detection of human population differentiation. *BMC Genetics*, 8:21, 2007. (PMID: 17498298; PMCID: PMC1876243)
185. Lappalainen J, Krupitsky E, **Kranzler HR**, Luo X, Remizov M, Pchelina S, Taraskina A, Zvartau E, Räsänen P, Makikyro T, Somberg LK, Krystal JH, Stein MB, Gelernter J: Mutation screen of the *GAD2* gene and association study of alcoholism in three populations. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 144B:183-192, 2007. (PMID: 17034009)

186. Arias A, Feinn R, Covault J, **Kranzler HR**: Memantine for alcohol dependence: An open-label pilot study. *Addictive Disorders and Their Treatment*, 6:77-84, 2007.
187. Luo X, **Kranzler HR**, Zuo L, Zhang H, Wang S, Gelernter J. *CHRM2* variation predisposes to personality traits of agreeableness and conscientiousness. *Human Molecular Genetics*, 16:1557-1568, 2007. (PMID: 17468496)
188. Zuo L, **Kranzler HR**, Luo X, Covault J, Gelernter J: *CNR1* variation modulates risk for drug and alcohol dependence. *Biological Psychiatry*, 62:616-626, 2007. (PMID: 17590536)
189. Pierucci-Lagha A, Gelernter J, Chan G, Arias A, Cubells JF, Farrer L, **Kranzler HR**. Reliability of DSM-IV diagnostic criteria using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). *Drug and Alcohol Dependence*, 91: 85-90, 2007. (PMID: 17590536; PMCID: PMC2039919)
190. O'Malley S, Garbutt JC, Gastfriend DR, Dong Q, **Kranzler HR**. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent prior to treatment, *Journal of Clinical Psychopharmacology*, 27:507-512, 2007.
191. Tang Y, **Kranzler HR**, Gelernter J, Farrer LA, Cubells JF: Co-morbid psychiatric diagnoses and their association with cocaine-induced psychosis in cocaine-dependent subjects. *American Journal on Addictions*, 16:343-351, 2007. (PMID: 17882604)
192. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, **Kranzler HR**, Mann K, O'Malley SS, Swift RM: Topiramate for treating alcohol dependence: A multi-site randomized controlled trial. *JAMA*, 298:1641-1651, 2007.
193. Hirunsatit R, Ilomäki R, Malison R, Räsänen P, Ilomäki E, **Kranzler HR**, Kosten T, Sughondhabirom A, Thavichachart N, Tangwongchai S, Listman J, Mutirangura A, Gelernter J, Lappalainen J: Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (*SLC6A1*) in five populations: implications for pharmacogenetic research, *BMC Genetics* 8:71, 2007. (PMID: 17941974; PMCID: PMC2175509)
194. Bauer LO, Covault J, Harel O, Das S, Anton R, **Kranzler HR**. Variation in *GABRA2* predicts drinking behavior in Project MATCH subjects. *Alcoholism: Clinical and Experimental Research* 31:1780-1787, 2007.
195. Yang B, **Kranzler HR**, Zhao H, Gruen JR, Luo X, Gelernter J: Association of haplotypic variants in *DRD2*, *ANKK1*, *TTC12* and *NCAM1* to alcohol dependence in independent case-control and family samples. *Human Molecular Genetics*, 16:2844-2853, 2007. (PMID: 17761687)
196. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, **Kranzler HR**. Population-specific effects of the Asn40Asp polymorphism at the μ -opioid receptor locus (*OPRM1*) on HPA axis activation. *Pharmacogenetics and Genomics*, 17:1031-1038, 2007.

197. Gunthert KC, Conner TS, Armeli S, Tennen T, Covault C, **Kranzler HR**: Serotonin transporter gene polymorphism (5-HTTLPR) and anxiety reactivity in daily life: a daily process approach to gene-environment interaction, *Psychosomatic Medicine*, 69:762-768, 2007. (PMID: 17942837)
198. Anton RF, **Kranzler HR**, Breder C, Marcus RN, Carson WH, Han J: A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence, *Journal of Clinical Psychopharmacology*, 28:5-12, 2008. (PMID: 18204334)
199. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, (and in alphabetical order) Addolorato G, Anton RF, Ciraulo DA, **Kranzler HR**, Mann K, O'Malley SS, Swift RM, for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. *Archives of Internal Medicine*, 168: 1188-1199, 2008. (PMID: 18541827)
200. **Kranzler HR**, Gage A. Acamprosate efficacy in alcohol-dependent patients: Reanalysis of results from 3 pivotal trials, *American Journal on Addictions*, 17:70-76, 2008. (PMID: 18214726)
201. Soyka M, **Kranzler HR**, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, Möller H-J, the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. *World Journal of Biological Psychiatry*, 9:6-23, 2008. (PMID: 18273737)
202. Luo, X, **Kranzler HR**, Zuo L, Zhang H, Wang S, Gelernter J. *ADH7* variation modulates Extraversion and Conscientiousness in substance-dependent subjects. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 147B:179-186, 2008. (PMCID: PMC3160628)
203. **Kranzler HR**, Wilcox M, Weiss RD, Brady K, Hesselbrock V, Rounsaville B, Farrer L, Gelernter J. The validity of cocaine dependence subtypes, *Addictive Behaviors*, 33:41-53, 2008. (PMCID: PMC2111173)
204. Covault J, Gelernter J, Jensen K, Anton R, **Kranzler HR**. Markers in the 5' region of *GABRG1* associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent *GABRA2* gene, *Neuropsychopharmacology*, 33:837-848, 2008. (PMCID: PMC2743531)
205. Zhang H, **Kranzler HR**, Yang B, Luo X, Gelernter J: The *OPRD1* and *OPRK1* loci in alcohol or drug dependence: *OPRD1* variation modulates substance dependence risk. *Molecular Psychiatry*, 13: 531-543, 2008. (PMCID: PMC3163084)
206. **Kranzler HR**, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias AJ, Oncken C: Effects of aripiprazole on subjective and physiological responses to alcohol, *Alcoholism: Clinical and Experimental Research*, 32:573-579, 2008. (PMCID: PMC3159685)

207. Ittiwut C, Listman J, Mutirangura A, Malison R, Covault J, **Kranzler HR**, Sughondhabirom A, Thavichart N, Gelernter J. Inter-population linkage disequilibrium (LD) patterns of *GABRA2* and *GABRG1* genes at the GABA cluster locus on human chromosome 4. *Genomics*, 91:61-69, 2008. (PMCID: PMC2709929)
208. Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto R, Mäkelä R, **Kranzler HR**: Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. *Alcoholism: Clinical and Experimental Research*, 32:1-8, 2008. (PMCID: PMC2950972)
209. Yu Y, **Kranzler HR**, Panhuysen C, Weiss RD, Poling J, Farrer LA, Gelernter J: Substance dependence low density whole genome association study in two distinct American populations. *Human Genetics*, 123:495-506, 2008. (PMCID: PMC3428017)
210. Gacek P, Conner TS, Tennen H, **Kranzler HR**, Covault J: Tryptophan hydroxylase 2 gene and alcohol use among college students, *Addiction Biology* 13, 440-448, 2008. (PMCID: PMC2695976)
211. Luo X, Zuo L, **Kranzler H**, Zhang H, Wang S, Gelernter J. Multiple OPR genes influence personality traits in substance dependent and healthy subjects in two American populations. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 147B:1028-1039, 2008. (PMCID: PMC3162230)
212. Oncken C, Dornelas E, Greene J, Sankey H, Glassman A, Feinn R, **Kranzler HR**: Nicotine gum for pregnant smokers: a randomized controlled trial, *Obstetrics and Gynecology*, 112:859-867, 2008. (PMCID: PMC2630492)
213. **Kranzler HR**, Stephenson JJ, Montejano L, Wang S, Gastfriend DR: Persistence with oral naltrexone for alcohol treatment: Implications for healthcare utilization, *Addiction*, 103: 1801-1808, 2008. (PMCID: PMC2652482)
214. Armeli S, Conner TS, Covault J, Tennen H, **Kranzler HR**: A serotonin transporter gene polymorphism (5-HTTLPR), drinking-to-cope motivation, and negative life events among college students, *Journal of Studies on Alcohol and Drugs*, 69:814-823, 2008. (PMCID: PMC2583385)
215. Hussain N, Krueger W, Covault J, Walsh S, **Kranzler HR**, Oncken C: Effects of prenatal tobacco exposure on gene expression profiling in umbilical cord tissue, *Pediatric Research*, 64:147-153, 2008. (PMCID: PMC2624573)
216. Arias AJ, Gelernter J, Chan G, Weiss W, Brady KT, Farrer L, **Kranzler HR**. Correlates of co-occurring ADHD in drug-dependent subjects: Prevalence and features of substance dependence and psychiatric disorders, *Addictive Behaviors*, 33:1199-1207, 2008. (PMCID: PMC2532519)
217. Yang BZ, **Kranzler HR**, Zhao H, Gruen JR, Luo X, Gelernter J: Haplotypic variants in *DRD2*, *ANKK1*, *TTC12* and *NCAM1* are associated with comorbid alcohol and drug dependence. *Alcoholism: Clinical and Experimental Research*, 32: 2117-2127, 2008. (PMCID: PMC2975565)

218. Luo X, Zuo L, **Kranzler HR**, Wang S, Anton RF, Gelernter J: Recessive genetic mode of an *ADH4* variant in substance dependence in African-Americans: a model of utility of the HWD test, *Behavioral and Brain Functions*, 18;4:42, 2008. (PMCID: PMC2563013)
219. Ford J, Gelernter J, DeVoe JS, Zhang W, Weiss RD, Brady K, Farrer L, **Kranzler HR**: Association of psychiatric and substance use disorder comorbidity with cocaine dependence severity and treatment utilization in cocaine-dependent individuals. *Drug and Alcohol Dependence*, 99:193–203, 2009. (PMCID: PMC2745327)
220. Pettinati HM, Gastfriend DR, Dong Q, **Kranzler HR**, O'Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research*, 33:350-356, 2009. (PMCID: PMC2976586)
221. Gelernter J, **Kranzler HR**, Panhuysen C, Weiss RD, Brady K, Poling J, Farrer, L: Dense genomewide linkage scan for alcohol dependence in African-Americans: Significant linkage on chromosome 10, *Biological Psychiatry*, 65:111-115, 2009. (PMCID: PMC2646253)
222. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, **Kranzler HR**: Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. *Drug and Alcohol Dependence*, 99:345-349, 2009. (PMCID: PMC3166770)
223. Farrer LA, **Kranzler HR**, Yu Y, Weiss RD, Brady KT, Cubells JF, Gelernter J: Association of variants in *MANEA* with cocaine-related behaviors, *Archives of General Psychiatry*, 66:267-274, 2009. (PMCID: PMC2758158)
224. **Kranzler HR**, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, Burian L, Covault J: Association of markers in the 3' region of the GluR5 kainate receptor subunit gene (*GRIK1*) to alcohol dependence. *Alcoholism: Clinical and Experimental Research*, 33:1–6, 2009. (PMCID: PMC2772659)
225. Jensen KP, Conner TS, Covault J, Tennen H, **Kranzler HR**, Furneaux HM. A common polymorphism in the 3'UTR of serotonin receptor 1B mRNA attenuates regulation by mir-96 and associates with aggressive human behavior, *Molecular Psychiatry*, 14: 381-389, 2009. (PMCID: PMC3162374)
226. Zuo L, **Kranzler HR**, Luo X, Yang BZ, Weiss R, Brady K, Poling J, Farrer L, Gelernter J: Interaction between two independent *CNR1* variants increases risk for cocaine dependence in European Americans: A replication study in family-based and population-based samples, *Neuropsychopharmacology*, 34:1504-1513, 2009. (PMCID: PMC2879626)
227. Feinn R, Gelernter J, Cubells JF, Farrer L, **Kranzler HR**: Sources of unreliability in the diagnosis of substance dependence. *Journal of Studies on Alcohol and Drugs*, 70:475-481, 2009. (PMCID: PMC2670752)
228. Zuo L, Luo X, Listman JB, **Kranzler HR**, Wang S, Anton RF, Blumberg HP, Stein MB, Pearlson GD, Covault J, Charney DS, van Kammen DP, Price LH, Lappalainen J, Cramer J, Krystal JH, Gelernter J: Population admixture modulates risk for alcohol dependence, *Human Genetics*, 125:605-13, 2009. (PMCID: PMC2777998)

229. Zhang H, **Kranzler HR**, Weiss RD, Luo X, Brady KT, Anton RF, Farrer LA, Gelernter J. Pro-opiomelanocortin gene variation related to alcohol or drug dependence: evidence and replications across family- and population-based studies, *Biological Psychiatry*, 66:128–136, 2009. (PMCID: PMC2896237)
230. Niciu MJ, Chan G, Gelernter J, Arias AJ, Douglas K, Weiss R, Anton RF, Farrer L, Cubells JF, **Kranzler HR**: Subtypes of major depression in substance dependence, *Addiction* 104:1700–1709, 2009. (PMCID: PMC2980795<http://www.ncbi.nlm.nih.gov/sites/pmctopmid> - NIHMSEXPL)
231. **Kranzler HR**, Tennen H, Armeli S, Chan G, Covault J, Arias AJ, Oncken C: Targeted naltrexone for problem drinkers, *Journal of Clinical Psychopharmacology*, 29:350-357, 2009. (PMCID: PMC3184851)
232. Oncken C, Chan G, Campbell W, Hatsukami D, **Kranzler HR**: Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers, *Journal of Maternal, Fetal, and Neonatal Medicine*, 22:751-758, 2009. (PMCID: PMC3169999)
233. Halder I, Yang BZ, **Kranzler HR**, Stein M, Shriver M, Gelernter J: Measurement of admixture proportions and description of admixture structure in different US populations, *Human Mutation*, 30:1299-1309, 2009. (PMCID: PMC2867064<http://www.ncbi.nlm.nih.gov/sites/pmctopmid> - NIHMSEXPL)
234. Xie P, **Kranzler HR**, Poling J, Anton R, Brady K, Weiss RD, Farrer L, Gelernter J: The interactive effect of stressful life events and the serotonin transporter 5-HTTLPR polymorphism on PTSD diagnosis, *Archives of General Psychiatry*, 66:1201-1209, 2009. (PMCID: PMC2867334)
235. Zhang H, **Kranzler HR**, Poling J, Gruen JR, Gelernter J: Cognitive flexibility is associated with *KIBRA* variant and modulated by recent tobacco use, *Neuropsychopharmacology*, 34:2508-2516, 2009. (PMCID: PMC2898508)
236. Zuo L, Luo X, **Kranzler HR**, Lu L, Rosenheck RA, Cramer J, van Kammen DP, Erdos J, Charney DS, Krystal J, Gelernter J. Association study of *DTNBP1* with schizophrenia in a US sample, *Psychiatric Genetics*, 19:292-304, 2009. (PMCID: PMC2771321)
237. Tremblay KA, Bona JM, **Kranzler HR**: Effects of a diagnosis or family history of alcoholism on the taste intensity and hedonic value of sucrose, *American Journal on Addictions*, 18:494-499, 2009. (PMCID: PMC2862626)
238. Tang Y, **Kranzler HR**, Gelernter J, Farrer LA, Cubells JF: Transient cocaine-associated behavioral symptoms rated with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP), *American Journal on Addictions*, 18:339-345, 2009. (PMCID: PMC2878659)
239. Zuo L, Gelernter J, **Kranzler HR**, Stein MB, Zhang H, Wei F, Sen S, Poling J, Luo X. *ADH1A* variation predisposes to personality traits and substance dependence, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 153B:376-386, 2010. (PMCID: PMC2861415)

240. **Kranzler HR**, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. In Addolorato G, Leggio L (Eds) Old and new pharmacotherapies in the management of patients with alcohol dependence. *Current Pharmaceutical Design*, 16:2141-2148, 2010. (PMCID: PMC4142701)
241. Douglas K, Gelernter J, Chan G, Arias AJ, Anton RF, Weiss RD, Brady K, Farrer L, **Kranzler HR**: Adverse childhood events as risk factors for substance dependence: partial mediation by mood and anxiety disorders, *Addictive Behaviors*, 35:7-13, 2010. (PMCID: PMC2763992)
242. Conner TS, Jensen KP, Tennen H, Covault J, Furneaux HM, **Kranzler HR**: Functional polymorphisms in the serotonin 1B receptor gene (*HTR1B*) predict self-reported anger and hostility among young men, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 153B:67-78, 2010. (PMCID: PMC3312780)
243. Leamon MH, Flower K, Salo RE, Nordahl TE, **Kranzler HR**, Galloway GP: Methamphetamine and paranoia: The Methamphetamine Experience Questionnaire, *American Journal on the Addictions*, 19:155-68, 2010. (PMCID: PMC3168774)
244. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, **Kranzler HR**, the HALT-C Trial Group: A functional serotonin transporter gene polymorphism and depressive symptoms associated with interferon- α treatment. *Psychosomatics*, 51:137-148, 2010. (PMCID: PMC3746312).
245. Kalayasiri R, Gelernter J, Farrer L, Weiss R, Brady K, Gueorguieva R, **Kranzler HR**, Malison RT: Adolescent cannabis use increases risk for cocaine-induced paranoia. *Drug and Alcohol Dependence*, 107:196-201, 2010 (PMCID: PMC2821949)
246. Das S, Harel O, Dey D, Covault J, **Kranzler HR**: Analysis of extreme drinking in patients with alcohol dependence using Pareto regression, *Statistics in Medicine*, 29: 1250-1258, 2010 (PMCID: PMC2894470)
247. Listman J, Hasin D, **Kranzler HR**, Malison RT, Mutirangura A, Sughondhabirom A, Aharonavich E, Weizman A, Frisch A, Gelernter J: Identification of population substructure among Jews using STR markers and dependence on reference populations included, *BMC Genetics*, 11:48, 2010 (PMCID: PMC2896335)
248. Panhuysen CI, **Kranzler HR**, Yu Y, Weiss RD, Brady K, Poling J, Farrer LA, Gelernter J: Confirmation and generalization of an alcohol dependence locus on chromosome 10q, *Neuropsychopharmacology*, 35:1325-1332, 2010. (PMCID: PMC28557598)
249. Zhang H, Gelernter J, Gruen JR, **Kranzler HR**, Herman AI, Simen AA. Functional impact of a single nucleotide polymorphism in the *OPRD1* promoter region, *Journal of Human Genetics*, 55:278-284, 2010. (PMCID: PMC2876206)
250. Sen S, **Kranzler HR**, Chan G, Krystal J, Speller H, Gelernter J, Guille C: A prospective cohort study investigating factors associated with depression during medical internship, *Archives of General Psychiatry*, 67:557-565, 2010. (PMID: 20368500)
251. **Kranzler HR**, Stephenson JJ, Montejano L, Wang S, Gastfriend DR: Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured

- population, *Alcoholism: Clinical and Experimental Research*, 34:1090-1097, 2010. (PMCID: PMC3159684)
252. Xie P, **Kranzler HR**, Poling J, Stein MB, Anton RF, Farrer LA, Gelernter J. Interaction of *FKBP5* with childhood adversity on risk for post-traumatic stress disorder. *Neuropsychopharmacology*, 35:1684-1692, 2010. (PMCID: PMC2946626)
 253. Arias AJ, Feinn F, Oncken C, Covault J, **Kranzler HR**: Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. *Journal of Clinical Psychopharmacology*, 30:318-22, 2010. (PMCID: PMC3157084)
 254. Sherva R, **Kranzler HR**, Yu Y, Poling J, Arias AJ, Anton RF, Oslin D, Cubells JF, Farrer LA, Gelernter J: Polymorphisms in nicotinic acetylcholine receptors are associated with multiple substance dependence phenotypes, *Neuropsychopharmacology*, 35:1921-1931, 2010 (PMCID: PMC3055642)
 255. Zhang H, **Kranzler HR**, Poling J, Gelernter J: Variation in the nicotinic acetylcholine receptor gene cluster *CHRNA5–CHRNA3–CHRNA4* and its interaction with recent tobacco use influence cognitive flexibility, *Neuropsychopharmacology*, 35:2211-24, 2010. (PMCID: PMC3055317)
 256. Mark TL, Montejano L, **Kranzler HR**, Chalk M, Gastfriend DR. Comparison of healthcare utilization among patients treated with alcohol dependence medications, *American Journal of Managed Care*, 16:879-88, 2010. (PMCID: PMC4160801)
 257. Herman AI, Conner TS, Anton RF, Gelernter J, **Kranzler HR**, Covault J: Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics, *Addiction Biology*, 16:124-32, 2011. (PMCID: PMC2888710)
 258. Malison R, Kalayasiri R, Sanichwankul K, Sughondhabiroom A, Mutirangura A, Pittman B, Gueorguieva R, **Kranzler HR**, Gelernter J: Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA), *Addictive Behaviors*, 36:156-60, 2011. (PMCID: PMC2981662)
 259. **Kranzler HR**, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C. A double-blind, randomized trial of sertraline for alcohol dependence: Moderation by age of onset and 5-hydroxytryptamine transporter-linked promoter region genotype. *Journal of Clinical Psychopharmacology*, 31:22-30, 2011. (PMCID: PMC3130300).
 260. Leventhal AM, Gelernter J, Oslin D, Anton RF, Farrer LA, **Kranzler HR**. Agitated depression in substance dependence, *Drug and Alcohol Dependence*, 116:163–169, 2011. (PMCID: PMC3105217)
 261. Cui DH, Zhang H, Yang BZ, Listman JB, Li D, Price LH, Carpenter LL, Tyrka AR, Anton RF, **Kranzler HR**, Gelernter J. Variation in *NGFB* is associated with primary affective disorders in women, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 156:401-12, 2011. (PMCID: PMC3108453)
 262. Soyka M, **Kranzler HR**, van den Brink W, Krystal J, Möller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 2: Opioid Dependence, *World Journal of Psychiatry*, 12: 160-187, 2011. (PMID: 21486104)

263. Milivojevic V, **Kranzler HR**, Gelernter J, Burian L, Covault J. Variation in genes encoding the neuroactive steroid synthetic enzymes 5 α -reductase type 1 and 3 α -reductase type 2 is associated with alcohol dependence, *Alcoholism: Clinical and Experimental Research*, 35:946-952, 2011. (PMCID: PMC3083475)
264. Chan G, Gelernter J, Oslin D, Farrer L, **Kranzler HR**. Empirically derived subtypes of opioid use and related behaviors, *Addiction*, 106:1146-1154, 2011. (PMCID: PMC3164489)
265. Han S, Yang B, **Kranzler HR**, Oslin D, Anton R, Gelernter J. Association of *CHRNA4* polymorphisms with smoking behavior in two populations, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 156:421-9, 2011. (PMCID: PMC3742073)
266. Douglas K, Chan G, Gelernter J, Arias AJ, Anton RF, Poling J, Farrer L, **Kranzler HR**. 5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder, *Psychiatric Genetics*, 21:240-8, 2011 (PMCID: PMC3119731)
267. Xie P, **Kranzler HR**, Krauthammer M, Cosgrove KP, Oslin D, Anton RF, Farrer LA, Picciotto MR, Zhao H, Gelernter J. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. *Biological Psychiatry*, 70:528-36, 2011. (PMCID: PMC3199609)
268. Yang B, Han S, **Kranzler HR**, Farrer LA, Gelernter J. A genomewide linkage scan of cocaine dependence and major depressive episode in two populations, *Neuropsychopharmacology*, 36:2422-30, 2011. (PMCID: PMC3194068)
269. **Kranzler HR**, Feinn R, Nelson E, Covault J, Anton RF, Farrer L, Gelernter J. A *CRHR1* haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 156:960-8, 2011. (PMCID: PMC3227028)
270. Chen J, Brunzell DH, Jackson K, van der Vaart A, Ma JZ, Payne TJ, Sherva R, Farrer LA, Gejman P, Levinson DF, Holmans P, Aggen SH, Damaj I, Kuo PH, Webb BT, Anton R, **Kranzler HR**, Gelernter J, Li MD, Kendler KS, Chen X. *ACSL6* is associated with the quantity of cigarettes smoked and its expression is altered by chronic nicotine exposure, *PLoS One*. 2011;6:e28790. (PMCID: PMC3243669)
271. Ittiwut R, Listman JB, Ittiwut C, Cubells JF, Weiss RD, Brady K, Oslin D, Farrer LA, **Kranzler HR**, Gelernter J. Association between polymorphisms in catechol-O-methyltransferase (*COMT*) and cocaine-induced paranoia in European-American and African-American populations, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 156B:651-60, 2011. (PMCID: PMC3864552)
272. Arias AJ, Chan G, Gelernter J, Farrer L, **Kranzler HR**. Variation in *OPRM1* and risk of suicidal behavior in drug-dependent individuals, *American Journal on Addictions*, 21:5-10, 2012. (PMCID: PMC3674102)
273. Xie P, **Kranzler HR**, Zhang H, Oslin D, Anton RF, Farrer LA, Gelernter J. Childhood adversity increases risk for nicotine dependence and interacts with $\alpha 5$ nicotinic

- acetylcholine receptor genotype specifically in males, *Neuropsychopharmacology*, 37:669-76, 2012. (PMCID: PMC3260970)
274. Zuo L, Gelernter J, Zhang CK, Zhao H, **Kranzler HR**, Malison RT, Li CS, Wang F, Zhang XY, Deng HW, Krystal JH, Zhang F, Luo X. Genome-wide association study of alcohol dependence implicates *KIAA0040* on chromosome 1q, *Neuropsychopharmacology*, 37:581-2, 2012. (PMCID: PMC3242317).
275. Li G, Gelernter J, **Kranzler HR**, Zhao H. M³: An improved SNP calling algorithm for Illumina BeadArray data, *Bioinformatics*, 28:358-65, 2012. (PMCID: PMC3268244)
276. **Kranzler HR**, Feinn R, Armeli S, Tennen H. Comparison of alcoholism subtypes as moderators of the response to sertraline treatment, *Alcoholism: Clinical and Experimental Research*, 36:509-516, 2012. (PMCID: PMC3235238)
277. Ittiwut C, Yang BZ, **Kranzler HR**, Anton RF, Hirunsatit R, Weiss RD, Covault J, Farrer LA, Gelernter J. *GABRG1* and *GABRA2* variation associated with alcohol dependence in African Americans, *Alcoholism: Clinical and Experimental Research* 36:588-593, 2012. (PMCID: PMC3250564)
278. **Kranzler HR**, Armeli S, Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence, *Alcoholism: Clinical and Experimental Research*, 36:739-744, 2012. (PMCID: PMC3721339)
279. Li D, Zhao H, **Kranzler HR**, Oslin D, Anton RF, Farrer LA, Gelernter J. Association of *COL25A1* with comorbid antisocial personality disorder (ASPD) and substance dependence, *Biological Psychiatry*, 71:733-40, 2012. (PMCID: PMC3268244)
280. Zhang H, Wang F, **Kranzler HR**, Anton RF, Gelernter J. Variation in regulator of G-Protein signaling 17 Gene (*RGS17*) is associated with multiple substance dependence diagnoses, *Behavioral and Brain Functions*, 8:23, 2012. (PMCID: PMC3406967)
281. Chen XD, Xiong DH, Yang TL, Pei YF, Guo YF, Li J, Yang F, Pan F, Tan LJ, Yan H, Liu XG, Lei SF, Li X, Ning LL, Zhu XZ, Levy S, **Kranzler HR**, Farrer LA, Gelernter J, Recker RR, Deng HW. *ANKRD7* and *CYTL1* are novel risk genes for alcohol drinking behavior. *Chinese Medical Journal (English)*, 125:1127-34, 2012. (PMCID: PMC4174677)
282. Sun J, Bi J, Chan G, Oslin D, Farrer L, Gelernter J, **Kranzler HR**. Improved methods to identify stable, highly heritable subtypes of opioid use and related behaviors, *Addictive Behaviors*, 37:1138-44, 2012. (PMCID: PMC3395719)
283. Bauer LO, Yang BZ, Houston RJ, **Kranzler HR**, Gelernter J. *GABRA2* genotype, impulsivity, and body mass. *American Journal on Addictions*, 21: 404-410, 2012. (PMCID: PMC3773931)
284. Wang F, Gelernter J, **Kranzler HR**, Zhang H. Identification of *POMC* exonic variants associated with substance dependence and body mass index. *PLoS One* 7(9): e45300, 2012 (PMCID: PMC3444488)
285. King AC, Cao D, O'Malley SS, **Kranzler HR**, Cai X, deWit H, Matthews AK, Stachowiak RJ. Effects of naltrexone on smoking cessation outcomes and weight gain

- in nicotine-dependent men and women, *Journal of Clinical Psychopharmacology*, 32:630-6, 2012. (PMCID: PMC4640209).
286. **Kranzler HR**, McKay JR. Personalized treatment of alcohol dependence. *Current Psychiatry Reports*, 14:486-93, 2012. (PMID: 22810115)
 287. Lieberman R, Levine ES, **Kranzler HR**, Abreu C, Covault J. Pilot study of iPSC-derived neural cells to examine biological effects of alcohol on human neurons *in vitro*, *Alcoholism: Clinical and Experimental Research*, 36:1678-87, 2012. (PMCID: PMC3424319)
 288. Zhang H, Herman A, **Kranzler HR**, Anton RF, Simen A, Gelernter J. Hypermethylation of *OPRM1* promoter region in European Americans with alcohol dependence. *Journal of Human Genetics*, 57:670-5, 2012. (PMCID: PMC3481015)
 289. Han S, Yang B, **Kranzler HR**, Oslin D, Anton RF, Farrer LA, Gelernter J. Linkage analysis followed by association show *NRG1* associated with cannabis dependence in African-Americans, *Biological Psychiatry*, 72:637-44, 2012 (PMCID: PMC3699339)
 290. Morgenstern J, Kuerbis AN, Kahler CW, Bux DA Jr., **Kranzler HR**. A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men, *Journal of Consulting and Clinical Psychology*, 80:863-75, 2012 (PMCID: PMC3458143)
 291. Xie P, **Kranzler HR**, Farrer F, Gelernter J. Serotonin transporter 5-HTTLPR genotype moderates the effects of childhood adversity on posttraumatic stress disorder risk: A replication study, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 159B:644-52, 2012. (PMCID: PMC3428016)
 292. Peer P, Rennert L, Lynch, KG, Farrer F, Gelernter J, **Kranzler HR**. Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorder diagnoses in a substance dependent sample, *Drug and Alcohol Dependence*, 127: 215-219, 2013. (PMCID: PMC3727225)
 293. **Kranzler HR**, Armeli S, Covault J, Tennen H. Variation in *OPRM1* moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. *Addiction Biology*, 18:193-201, 2013 (PMCID: PMC3473112)
 294. Zhang H, Herman AI, **Kranzler HR**, Anton RF, Zhao H, Zheng W, Gelernter J. Array-based profiling of DNA methylation changes associated with alcohol dependence, *Alcoholism: Clinical and Experimental Research*, 37 Suppl 1:E108-15, 2013. (PMCID: PMC3511647).
 295. Dornelas E, Oncken C, Greene J, **Kranzler HR**. Major depression and PTSD in pregnant smokers enrolled in a nicotine gum treatment trial, *American Journal on Addictions*, 22:54-9, 2013. (PMCID: PMC23398227).
 296. Uhart M, Weerts EM, McCaul ME, Guo X, Yan X, **Kranzler HR**, Li N, Wand GS. *GABRA2* markers moderate the subjective effects of alcohol, *Addiction Biology*, 18:357-369, 2013 (PMCID: PMC3402582)
 297. Chen ACH, Morgenstern J, Davis CM, Kuerbis AN, Covault J, **Kranzler HR**. Variation in mu-opioid receptor gene (*OPRM1*) as a moderator of naltrexone treatment

- to reduce heavy drinking in a high functioning cohort. *Journal of Alcoholism and Drug Dependence* 1:101, 2013. (PMCID: PMC3983993)
298. **Kranzler HR**, Armeli S, Tennen H, Covault J. 5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity, *Addiction Biology*, 18:1024-31, 2013 (PMCID: PMC3578002).
299. Sen S, **Kranzler HR**, Didwania A, Schwartz A, Amarnath S, Kolars J, Dalack G, Guille C. Effects of the 2011 duty hour reforms on interns and their patients: A prospective longitudinal cohort study, *JAMA Internal Medicine*, 25:1-6, 2013.
300. Chakravorty S, Grandner MA, **Kranzler HR**, Mavandadi S, Kling MA, Perlis ML, Oslin DW. Insomnia in alcohol dependence: Predictors of symptoms in a sample of veterans referred from primary care, *American Journal on Addictions*, 22:266-70, 2013. (PMCID: PMC4393849)
301. Zhang H, Wang F, **Kranzler HR**, Zhao H, Gelernter J. Profiling of childhood adversity-associated DNA methylation changes in alcoholic patients and healthy controls. *PLoS One*, 8: e65648, 2013. (PMCID: PMC3683055)
302. McCarthy MJ, Fernandes M, **Kranzler HR**, Covault J, Welsh D. Circadian clock period inversely correlates with illness severity in cells from patients with alcohol use disorders. *Alcoholism: Clinical and Experimental Research*, 37:1304-1310, 2013. (PMCID: PMC3706548)
303. Han S, Gelernter J, **Kranzler HR**, Yang BZ. Ordered subset linkage analysis based on admixture proportion identifies new linkage evidence for alcohol dependence in African-Americans. *Human Genetics*, 132:397-403, 2013. (PMCID: PMC3751162).
304. Nocente R, Vitali M, Balducci G, Enea D, **Kranzler HR**, Ceccanti M. Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of co-occurring alcohol and nicotine addiction? *American Journal on the Addictions*, 22:453-9, 2013.
305. Xie P, **Kranzler HR**, Yang C, Zhao H, Farrer LA, Gelernter J. Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder, *Biological Psychiatry*. 74:656–663, 2013. (PMCID: PMC3810148)
306. Han S, Yang B, **Kranzler HR**, Liu X, Zhao H, Farrer LA, Boerwinkle E, Potash J, Gelernter J. Integrating GWASs and human protein interaction networks identifies a gene subnetwork underlying alcohol dependence, *American Journal of Human Genetics*, 93:1027-34, 2013. (PMCID: PMC3853414)
307. Wang LS, Jiao Y, Huang Y, Liu X, Cao Y, Gibson G, Bennett B, Hamre KM, Li D, Zhao H, Gelernter J, **Kranzler HR**, Farrer LA, Lu L, Williams R, Wang Y, Gu W. Critical evaluation of transcription factor Atf2 as a candidate modulator of alcohol preference in mouse and human populations, *Genetics and Molecular Research*, 12:5992-6005, 2013. (PMCID: PMC4108070)
308. Sartor CE, **Kranzler HR**, Gelernter J. Rate of progression from first use to dependence on cocaine or opioids: a cross-substance examination of associated demographic, psychiatric, and childhood risk factors, *Addictive Behaviors*, 39:473-9, 2014. (PMCID: PMC3855905)

309. Jensen KP, Stein MB, **Kranzler HR**, Yang B, Farrer LA, Gelernter J. The α -endomannosidase gene (*MANEA*) is associated with panic disorder and social anxiety disorder, *Translational Psychiatry*, 4:e353, 2014. (PMCID: PMC3905232)
310. Zindel L, **Kranzler HR**. Pharmacotherapy of alcohol use disorders: Seventy-five years of progress. *Journal of Studies on Alcohol and Drugs*, Suppl. 17:79-88, 2014. (PMCID: PMC4453501)
311. Rennert L, Denis C, Peer K, Lynch KG, Gelernter J, **Kranzler HR**. DSM-5 Gambling Disorder: Prevalence and characteristics in a substance use disorder sample, *Experimental and Clinical Psychopharmacology*, 22:50-6, 2014. (PMCID: PMC4019046)
312. Gelernter J, Sherva R, Koesterer R, Almasy L, Zhao H, **Kranzler HR**, Farrer L. Genomewide association study of cocaine dependence and related traits: FAM53B identified as a risk gene. *Molecular Psychiatry*, 19:717-723, 2014. (PMCID: PMC3865158)
313. Gelernter J, **Kranzler HR**, Sherva R, Almasy L, Koesterer R, Anton R, Preuss UW, Ridinger M, Rujescu D, Wodarz N Zill P, Han S, Zhao H, Farrer LA. Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci, *Molecular Psychiatry*, 19:41-49, 2014. (PMCID: PMC24166409)
314. Li D, Sulovari A, Cheng C, Zhao H, **Kranzler HR**, Gelernter J. Association of gamma-aminobutyric acid A Receptor $\alpha 2$ gene (*GABRA2*) with alcohol use disorder. *Neuropsychopharmacology*, 39:907-18, 2014. (PMCID: PMC3924525)
315. Jensen KP, **Kranzler HR**, Stein MB, Gelernter J. The effects of a *MAP2K5* microRNA target site SNP on risk for anxiety and depressive disorders, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 165:175-83, 2014. (PMCID: PMC4174417)
316. Arias AJ, Covault J, Feinn R, Pond T, Yang B, Ge W, Oncken C, **Kranzler HR**. A *GABRA2* variant is associated with increased stimulation and 'high' following alcohol administration. *Alcohol and Alcoholism*, 49:1-9, 2014. (PMCID: PMC3865816).
317. Bi J, Gelernter J, Sun J, **Kranzler HR**. Comparing the utility of homogeneous subtypes of cocaine use and related behaviors with DSM-IV cocaine dependence as traits for genetic association analysis. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 165:148-56, 2014. (PMCID: PMC4149216)
318. Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, **Kranzler HR**. Topiramate for smoking cessation: a randomized, placebo-controlled, pilot study. *Nicotine & Tobacco Research*, 16:288-96, 2014. (PMCID: PMC3920334).
319. Quillen EE, Chen X-D, Almasy L, Yang F, He H, Li X, Wang X-Y, Liu T-Q, Hao W, Deng H-W, **Kranzler HR**, Gelernter J. ALDH2 is associated to alcohol dependence and is the major genetic determinant of "daily maximum drinks" in a GWAS study of an isolated rural Chinese sample, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 165:103-10, 2014. (PMCID: PMC4149216)

320. Greenfield TK, Ye Y, Bond J, Kerr WC, Nayak MB, Kaskutas LA, Anton RF, Litten RZ, **Kranzler HR**. Risks of alcohol use disorders related to drinking patterns in the US general population. *Journal of Studies on Alcohol and Drugs*, 75:319-27, 2014. (PMCID: PMC3965685)
321. Falk DE, Litten RZ, Anton RF, **Kranzler HR**, Johnson BA, and the *ACTIVE* Workgroup. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. *Journal of Studies on Alcohol and Drugs*, 75:335-346, 2014. (PMCID: PMC3965687)
322. **Kranzler HR**, Covault J, Feinn R, Armeli S, Tennen T, Arias AJ, Gelernter J, Oncken C, Pond T, Kampman KM. Topiramate treatment for heavy drinkers: Moderation by a *GRIK1* polymorphism, *American Journal of Psychiatry*, 171: 445-452, 2014. (PMCID: PMC3997125)
323. Sartor CE, **Kranzler HR**, Gelernter J. Characteristics and course of dependence in cocaine dependent individuals who never used alcohol or marijuana or used cocaine first. *Journal of Studies on Alcohol and Drugs*, 75:423-427, 2014. (PMCID: PMC3855905)
324. Levey DF, Le-Niculescu H, Frank J, Ayalew M, Jain N, Kirilin B, Learman R, Winiger E, Rodd Z, Shekhar A, Schork N, Kiefer F, Wodarz N, Müller-Myhsok B, Dahmen N, GESGA Consortium, Nöthen M, Sherva S, Farrer L, Smith AH, **Kranzler H**, Rietschel M, Gelernter J, Niculescu AB. Genetic risk prediction and neurobiological understanding of alcoholism. *Translational Psychiatry*, 4:e391, 2014. (PMCID: PMC4035721)
325. Sun J, Bi J, **Kranzler HR**. Multiview comodeling to improve subtyping and genetic association of complex diseases. *IEEE Journal of Biomedical and Health Informatics*, 18:548-54, 2014. (PMCID: PMC4158610)
326. Sun J, Bi J, **Kranzler HR**. Multi-view singular value decomposition for disease subtyping and genetic associations. *BMC Genetics*, 15:73, 2014. (PMCID: PMC4077642)
327. Gelernter J, **Kranzler HR**, Sherva R, Koesterer R, Almasy L, Zhao H, Farrer LA. Genomewide association study of opioid dependence and related traits: multiple associations mapped to calcium and potassium pathways. *Biological Psychiatry*, 76:66-74, 2014. (PMCID: PMC3992201)
328. Zhang H, Wang F, **Kranzler HR**, Yang C, Xu H, Wang Z, Zhao H, Gelernter J. Identification of methylation quantitative trait loci (mQTLs) influencing DNA methylation in the promoter regions of alcohol dependence risk genes, *Human Genetics*, 133:1093-104, 2014. (PMCID: PMC4127343)
329. Covault J, Pond T, Feinn R, Arias AJ, Oncken C, **Kranzler HR**. Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environment, *Psychopharmacology*, 231:3609-3618, 2014. (PMCID: PMC4181572)
330. Milivojevic V, Feinn R, **Kranzler HR**, Covault J. Variation in *AKR1C3*, which encodes the neuroactive steroid synthetic enzyme 3 α -HSD type 2 (17 β -HSD type 5),

- moderates the subjective effects of alcohol, *Psychopharmacology (Berl)* 231:3597-3608, 2014. (PMCID: PMC4135039)
331. Yang C, Li C, **Kranzler HR**, Farrer LA, Zhao H, Gelernter J. Exploring the genetic architecture of alcohol dependence in African-Americans via analysis of a genomewide set of common variants. *Human Genetics*, 133:617-24, 2014. (PMCID: PMC3988209)
 332. Xie P, **Kranzler HR**, Krystal J, Farrer L, Zhao H, Gelernter J. Deep resequencing of 17 glutamate system genes identifies rare variants in *DISC1* and *GRIN2B* affecting risk of opioid dependence. *Addiction Biology* 19:955-64, 2014. (PMCID: PMC3815683)
 333. Quinn AE, Rosen RK, McGeary JE, Amoa F, **Kranzler HR**, Francazio S, McGarvey ST, Swift RM. Translating the Semi-Structured Assessment for Drug Dependence and Alcoholism in the Western Pacific: Rationale, study design and reliability of alcohol dependence. *Alcohol and Alcoholism* 49:525-30, 2014. (PMCID: PMC4128669)
 334. **Kranzler HR**, Armeli S, Feinn R, Tennen H, Gelernter J, Covault J. *GRIK1* genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects, and desire to drink. *International Journal of Neuropsychopharmacology*, 17: 1549-1556, 2014. (PMCID: PMC4161658)
 335. **Kranzler HR**, Feinn R, Gelernter J, Pond T, Covault J. Topiramate's reduction of body mass index in heavy drinkers: Lack of moderation by a *GRIK1* polymorphism, *Experimental and Clinical Psychopharmacology*, 22:419-423, 2014. (PMCID: PMC4180772)
 336. Chen ACH, Davis CM, Kahler CW, Kuerbis AN, Covault J, **Kranzler HR**, Morgenstern J. 5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men, *Alcoholism: Clinical and Experimental Research*, 38:2362-8, 2014. (PMCID: PMC4177453)
 337. **Kranzler HR**, Armeli S, Tennen H, Gelernter J, Covault J. *GRIK1* genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate. *Experimental and Clinical Psychopharmacology*, 22:494-501, 2014. (PMCID: PMC4251491).
 338. Witkiewitz K, Falk DE, **Kranzler HR**, Litten RZ, Hallgren KA, O'Malley SS, Anton RF, Alcohol Clinical Trials Initiative Workgroup. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials, *Alcoholism: Clinical and Experimental Research* 38:2826-34, 2014. (PMCID: PMC4244651)
 339. Stout RL, Braciszewski JM, Subbaraman MS, **Kranzler HR**, O'Malley SS, Falk D. What happens when people discontinue taking medications? Lessons from COMBINE. *Addiction*, 109:2044-52, 2014. (PMCID: PMC4254710)
 340. Sartor C, Wang Z, Xu K, **Kranzler H**, Gelernter J. The joint effects of *ADH1B* variants and childhood adversity on alcohol-related phenotypes in African-American and European-American women and men. *Alcoholism: Clinical and Experimental Research*, 38: 2907-14, 2014. (PMCID: PMC4445128).

341. **Kranzler HR**, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment effects of topiramate treatment for heavy drinking, *Alcoholism: Clinical and Experimental Research*, 38:3017-23, 2014. (PMCID: PMC4293099)
342. Richardson TG, Minica C, Heron J, Tavare J, MacKenzie A, Day I, Lewis G, Hickman M, Vink JM, Gelernter J, **Kranzler HR**, Farrer L, Munafò M, Wynick D. Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and addictive phenotypes, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 165:654-64, 2014. (PMCID: PMC4388908)
343. O'Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, **Kranzler HR**. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. *Journal of Clinical Psychiatry*, 76:e207-e213, 2015. (PMCID: PMC4442987).
344. Gelernter J, **Kranzler HR**, Sherva R, Almasy L, Herman AI, Koesterer R, Zhao H, Farrer LA. Genome-wide association study of nicotine dependence in American populations: Identification of novel risk loci in both African-Americans and European-Americans. *Biological Psychiatry*, 77:493-503, 2015. (PMCID: PMC4386684)
345. Li D, Zhao H, **Kranzler HR**, Li MD, Jensen KP, Zayats T, Farrer LA, Gelernter J. Genome-wide association study of copy number variations (CNVs) with opioid dependence. *Neuropsychopharmacology*, 40:1016-26, 2015. (PMCID: PMC4330517)
346. Repunte-Canonigo V, Herman MA, Kawamura T, **Kranzler HR**, Sherva R, Gelernter J, Farrer LA, Roberto M, Sanna PP. Nf1 regulates alcohol dependence-associated excessive drinking and gamma-aminobutyric acid release in the central amygdala in mice and is associated with alcohol dependence in humans, *Biological Psychiatry*, 77:870-9, 2015. (PMCID: PMC4428692)
347. Sulovari A, **Kranzler HR**, Farrer LA, Gelernter J, Li D. Eye color: an ancestral indicator of alcohol dependence risk in European Americans, *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 168:347-53, 2015.
348. Chaudhary NS, Kampman KM, **Kranzler HR**, Grandner MA, Debbarma S, Chakravorty S. Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity. *Addictive Behaviors*, 50: 165-172, 2015. (PMCID: PMC4515378).
349. Denis CM, Gelernter J, Hart AB, **Kranzler HR**. Inter-observer reliability of DSM-5 Substance Use Disorders. *Drug and Alcohol Dependence*, 153:229-35, 2015. (PMCID: PMC4509850)
350. Hart AB, Lynch KG, Farrer LA, Gelernter J, **Kranzler HR**. Which alcohol use disorder criteria contribute to the association of *ADH1B* with alcohol dependence? *Addiction Biology*, 39:1312-27, 2015 (PMCID: PMC4515198)
351. Lieberman R, Joshi P, Shin D-G, **Kranzler HR**, Covault J. *GABRA2* alcohol dependence risk allele is associated with reduced expression of chromosome 4p12 *GABA_A* subunit genes in human neural cultures, *Alcoholism: Clinical and Experimental Research*, 39:1654-64, 2015. (PMCID: PMC4558268)

352. Hancock DB, Reginsson GW, Gaddis NC, Chen X, Saccone NL, Lutz SM, Qaiser B, Sherva R, Steinberg S, Zink F, Stacey SN, Glasheen C, Chen J, Gu F, Frederiksen BN, Loukola A, Gudbjartsson DF, Brüske I, Landi MT, Bickeböller H, Madden P, Farrer L, Kaprio J, **Kranzler HR**, Gelernter J, Baker TB, Kraft P, Amos CI, Caporaso NE, Hokanson JE, Bierut LJ, Thorgeirsson TE, Johnson EO, Stefansson K. Genome-wide meta-analysis reveals common splice site acceptor variant in *CHRNA4* associated with nicotine dependence, *Translational Psychiatry*, 5:e651, 2015.
353. Jensen KP, Herman AI, Morean ME, **Kranzler HR**, Gelernter J, Sofuoglu M. *FKBP5* variation is associated with the acute and chronic effects of nicotine, *Pharmacogenomics Journal*, 15:340-6, 2015. (PMCID: PMC4599366)
354. Jones JD, Comer SD, **Kranzler HR**. The pharmacogenetics of alcohol use disorder, *Alcoholism: Clinical and Experimental Research*, 39:391-402, 2015. (PMCID: PMC4348335)
355. Oncken C, Feinn R, Covault J, Duffy V, Dornelas E, **Kranzler HR**, Sankey H. Genetic vulnerability to menthol cigarette preference in women, *Nicotine & Tobacco Research*, 17:1416-20, 2015.
356. Sun J, **Kranzler HR**, Bi J. Refining multivariate disease phenotypes for high chip heritability. *BMC Genomics*, 8 Suppl 3:S3, 2015 (PMCID: PMC4582350)
357. Gilbert J, Schnoll R, Morrison MF, Srinivas SK, Pond T, Curtis B, Henry J, **Kranzler HR**. Smoking and cellular telephone use in pregnant women seeking pre-natal care: Opportunities for intervention, *Addictive Disorders and Their Treatment*, 14:203-2010, 2015. (PMCID: PMC4705558).
358. Hou J, Seneviratne C, Su X, Taylor J, Johnson B, Wang XQ, Zhang H, **Kranzler HR**, Kang J, Liu L. Subgroup identification in personalized treatment of alcohol dependence. *Alcoholism: Clinical and Experimental Research*, 39:1253-9, 2015. (PMCID: PMC4491003)
359. Xu K, **Kranzler HR**, Sherva R, Sartor CE, Almasy L, Koesterer R, Zhao H, Farrer LA, Gelernter J. Genome-wide association study for maximum number of alcohol drinks in European Americans and African Americans, *Alcoholism: Clinical and Experimental Research*, 39:1137-47, 2015. (PMCID: PMC4706077)
360. Witkiewitz K, Finney JW, Harris AHS, Kivlahan DR, **Kranzler HR**. Recommendations for the design and analysis of treatment trials for alcohol use disorders, *Alcoholism: Clinical and Experimental Research*, 39:1557-70, 2015 (PMCID: PMC4558228)
361. Witkiewitz K, Finney JW, Harris AHS, Kivlahan DR, **Kranzler HR**. Guidelines for the reporting of treatment trials for alcohol use disorders, *Alcoholism: Clinical and Experimental Research*, 39:1571-81, 2015. (PMCID: PMC4558296)
362. Sun J, **Kranzler HR**, Bi J. An effective method to identify heritable components from multivariate phenotypes. *PLoS One*, 10:e0144418, 2015. (PMCID: PMC4678282)
363. DeMartini KS, Gueorguieva R, Leeman RF, Corbin WR, Fucito LM, **Kranzler HR**, O'Malley SS. Longitudinal findings from a randomized clinical trial of naltrexone for

young adult heavy drinkers, *Journal of Consulting and Clinical Psychology*, 84:185-190, 2016.

364. **Kranzler HR**, Armeli, Wetherill R, Feinn R, Tennen H, Gelernter J, Covault J, Pond T. Self-efficacy mediates the effects of topiramate and *GRIKI* genotype on drinking. *Addiction Biology*, 21:450-9, 2016 (PMCID: PMC4468044)
365. Feinn R, Curtis B, **Kranzler HR**. Balancing risk and benefit in heavy drinkers treated with topiramate: Implications for personalized care. *Journal of Clinical Psychiatry* 77:e278–e282, 2016. (PMCID: PMC4845738)
366. Stringer S, Minică CC, Verweij KJH, Mbarek H, Derringer J, van Eijk KR, Isen JD, Loukola A, Maciejewski DF, Mihailov E, van der Most PJ, Sánchez-Mora C, Sherva R, Walters R, Ware JJ, Abdellaoui A, Bigdeli TB, Branje SJT, Brown SA, Bruinenberg B, Casas M, Esko T, Garcia-Martinez I, Gordon SD, Hartman CA, Henders AK, Heath AC, Hickie IB, Hickman M, Hopfer CJ, Hottenga JJ, Huizink AC, Irons DE, Kahn RS, Korhonen T, **Kranzler HR**, Krauter K, van Lier PAC, Lubke GH, Madden PAF, Mägi R, McGue MK, Medland SE, Meeus WHJ, Miller MB, Montgomery GW, Nivard MG, Nolte IM, Oldehinkel AJ, Qaiser B, Ramos-Quiroga JA, Richarte V, Rose RJ, Stallings MC, Stiby AI, Wall TL, Wright MJ, Koot HM, Hewitt JK, Ribasés M, Kaprio J, Boks MP, Snieder H, Munafò MR, Metspalu A, Gelernter J, Boomsma DI, Iacono WG, Martin NG, Gillespie NA, Derks EM, Vink JM. Genome wide association study of lifetime cannabis use based on a large meta-analytic sample of 32,330 subjects from the International Cannabis Consortium, *Translational Psychiatry*, Mar 29;6:e769, 2016. (PMCID: PMC4872459)
367. Sherva R, Wang Q, **Kranzler H**, Zhao H, Koesterer R, Herman A, Farrer L, Gelernter J. Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks, *JAMA Psychiatry*, 73:472-80, 2016. (PMCID: PMC4974817)
368. Nelson EC, Agrawal A, Heath AC, Sherva R, Zhang B, Al-Hasani R, Bruchas MR, Chou Y-L, Fakira AK, Farrer LA, Goate A, Gordon S, Henders AK, Hesselbrock V, Kapoor M, Lynskey MT, Madden PAF, Moron JA, Rice JP, Saccone NL, Schwab SG, Shand FL, Todorov AA, Wallace L, Wang T, Wray N, Zhou X, Degenhardt L, Martin NG, **Kranzler HR**, Gelernter J, Bierut LJ, Clark DJ, Montgomery GW. Evidence of *CNIH3* involvement in opioid dependence, *Molecular Psychiatry*, 21:608-14, 2016. (PMCID: PMC4740268)
369. Clarke TK, Smith AH, Gelernter J, **Kranzler HR**, Farrer LA, Hall LS, Fernandez-Pujals AM, MacIntyre DJ, Smith BH, Hocking LJ, Padmanabhan S, Hayward C, Thomson PA, Porteous DJ, Deary IJ, McIntosh AM. Polygenic risk for alcohol dependence associates with alcohol consumption, cognitive function and social deprivation in a population-based cohort. *Addiction Biology*, 21:469-80, 2016 (PMCID: PMC4600406)
370. Hallgren KA, Witkiewitz K, **Kranzler HR**, Falk DE, Litten RZ, O'Malley SS, Anton RF, Alcohol Clinical Trials Initiative (ACTIVE) Workgroup. Missing data in alcohol clinical trials with binary outcomes, *Alcoholism: Clinical and Experimental Research*, 40:1548-57, 2016. (PMCID: PMC27254113)
371. Lieberman L, Armeli S, Scott DM, **Kranzler HR**, Tennen H, Covault J. *FKBP5* genotype interacts with early life trauma to predict heavy drinking in college students.

American Journal of Medical Genetics (Neuropsychiatric Genetics), 171:879-87, 2016 (PMCID: PMC5045724)

372. Helstrom A, Blow FC, Slaymaker V, **Kranzler HR**, Leong S, Oslin D. Reductions in alcohol craving following naltrexone treatment for heavy drinking, *Alcohol and Alcoholism*, 51:562-6, 2016. (PMCID: PMC27402770)
373. Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen PH, Yang BZ, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, **Kranzler HR**, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Müller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nöthen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerström N, Scherbaum N, Schmääl C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PA, McGue M, Munafò MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL. Association of the *OPRM1* variant rs1799971 (A118G) with non-specific liability to substance dependence in a collaborative de novo meta-analysis of European-ancestry cohorts. *Behavior Genetics*, 46:151-69, 2016. (PMCID: PMC4752855)
374. Polimanti R, **Kranzler HR**, Gelernter J. Phenome-wide association study for alcohol and nicotine risk alleles in 26,394 women, *Neuropsychopharmacology*, 41:2688-96, 2016. (PMCID: PMC5026736)
375. Bold KW, Fucito LM, Corbin WR, DeMartini KS, Leeman RF, **Kranzler HR**, O'Malley SS. Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults. *Experimental and Clinical Psychopharmacology*, 24:367-375, 2016. (PMCID: PMC5111359)
376. Lieberman R, Levine E, **Kranzler HR**, Covault J. Examining FKBP5 mRNA expression in human iPSC-derived neural cells, *Psychiatry Research*, 247:172-181, 2016. (PMCID: PMC5191911)
377. Van Nest D, Hernandez N, **Kranzler HR**, Pierce RC, Schmidt HD. Effects of LY466195, a selective kainate receptor antagonist, on ethanol preference and drinking in rats. *Neuroscience Letters*, 639:8-12, 2016. (PMCID: PMC5272788)
378. Witkiewitz K, Hallgren KA, **Kranzler HR**, Mann KF, Hasin DS, Falk DE, Litten RZ, O'Malley SS, Anton RF. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels, *Alcoholism: Clinical and Experimental Research*, 41:179-186, 2017. (PMCID: PMC5205540)

379. Bold KW, Fucito LM, DeMartini KS, Leeman RF, **Kranzler HR**, Corbin WR, O'Malley SS. Urgency traits moderate daily relations between affect and drinking to intoxication in young adults, *Drug and Alcohol Dependence*, 170:59-65, 2017. (PMCID: PMC5183550)
380. Polimanti R, Wang Q, Meda SA, Patel KT, Pearlson GD, Zhao H, Farrer LA, **Kranzler HR**, Gelernter J. The interplay between risky sexual behaviors and alcohol dependence: risk alleles identified in a genome-wide investigation, *Neuropsychopharmacology*, 42:598-605, 2017. (PMCID: PMC27531626)
381. Jensen KP, Smith AH, Herman AI, Farrer LA, **Kranzler HR**, Sofuoglu M, Gelernter J. A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke. *Molecular Psychiatry*, 22:242-249, 2017. (PMCID: PMC27067016)
382. Wang Q, Polimanti R, **Kranzler HR**, Farrer L, Zhao H, Gelernter J. Genetic factor common to schizophrenia and HIV infection is associated with risky sexual behavior: Antagonistic vs. synergistic pleiotropic SNPs enriched for distinctly different biological functions. *Human Genetics*, 136:75-83, 2017. (PMCID: PMC5215962)
383. Xu H, Wang F, **Kranzler HR**, Gelernter J, Zhang H. Alcohol and nicotine codependence-associated DNA methylation changes in promoter regions of addiction-related genes, *Scientific Reports*, 7:41816, 2017. (PMCID: PMC5292964)
384. Smith AH, Jensen KP, Li J, Nunez Y, Farrer LA, Hakonarson H, Cook-Sather SD, **Kranzler HR**, Gelernter J. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of *OPRM1*. *Molecular Psychiatry*, 22: 346-352, 2017. (PMCID: PMC28115739)
385. Oncken C, Ricci KA, Kuo C-L, Dornelas E, **Kranzler HR**, Sankey HZ. Correlates of electronic cigarette use before and during pregnancy. *Nicotine and Tobacco Research*, 19:585-590, 2017.
386. Yang B-Z, Han S, **Kranzler HR**, Palmer AA, Gelernter J. Sex-specific linkage scans in opioid dependence. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*. 174:261-268, 2017.
387. Hasin DS, Wall M, Witkiewitz K, **Kranzler HR**, Falk D, Litten R, Mann K, O'Malley S, Scodes J, Robinson R, Anton RF. Change in non-abstinent WHO risk drinking levels and alcohol dependence: A 3-year follow-up study in the U.S. general population. *Lancet Psychiatry*, 4:469-476, 2017. (PMCID: PMC5536861)
388. Witkiewitz K, Wilson AD, Pearson MR, Hallgren KA, Falk DE, Litten RZ, **Kranzler HR**, Mann KF, Hasin DS, O'Malley SS, Anton RF. Temporal stability of heavy drinking days and drinking reductions among heavy drinkers in the COMBINE Study. *Alcoholism: Clinical and Experimental Research* 41:1054-1062, 2017. (PMCID: PMC5404970)
389. Polimanti R, Zhang H, Smith AH, Zhao H, Farrer LA, **Kranzler HR**, Gelernter J. Genome-wide association study of body mass index (BMI) in subjects with alcohol dependence. *Addiction Biology*, 22:535-549, 2017 (PMCID: PMC5102811)

390. Adkins A, Hack LM, Bigdeli TB, Williamson VS, McMichael GO, Mamdani M, Edwards A, Aliev F, Chan RF, Bhandari P, Rabbe RC, Alaimo JT, Blackwell GG, Moscatti AA, Poland RS, Rood B, Patterson DG, Walsh D, Collaborative Study of the Genetics of Alcoholism, Whitfield JB, Zhu G, Montgomery GW, Henders AK, Martin NG, Heath AC, Madden PA, Frank J, Ridinger M, Wodarz N, Soyka M, Zill P, Ising M, Nothen MM, Kiefer F, Rietschel M, German Study of the Genetics of Addiction, Gelernter J, Sherva R, Koesterer R, Almasy L, Zhao H, **Kranzler HR**, Farrer LA, Maher BS, Prescott CA, Dick DM, Bacanu S-A, Mathies LG, Davies AG, Vladimirov VI, Grotewiel M, Bowers MS, Bettinger JC, Webb BT, Miles MF, Kendler KS, Riley B. Genomewide association study of alcohol dependence identifies risk loci altering ethanol-response behaviors. *Alcoholism: Clinical and Experimental Research*, 41: 911-928, 2017. (PMCID: PMC5404949)
391. Sippel LM, Han S, Watkins LE, Harpaz-Rotem I, Southwick SM, Krystal JH, Olf M, Sherva R, Farrer LA, **Kranzler HR**, Gelernter J, and Pietrzak RH. Oxytocin receptor gene polymorphisms, attachment, and PTSD: Results from the National Health and Resilience in Veterans Study. *Journal of Psychiatric Research*, 94:139-147, 2017. (PMCID: PMC5605420)
392. Justice AC, McGinnis KA, Tate J, Xu K, Becker WC, Zhao H, Gelernter J, **Kranzler HR**. Validating harmful alcohol use as a phenotype for genetic discovery using phosphatidylethanol and a polymorphism in *ADH1B*. *Alcoholism Clinical and Experimental Research*, 41:998-1003, 2017. (PMCID: PMC5501250)
393. Polimanti R, Meda SA, Pearlson GD, Zhao H, Sherva R, Farrer LA, **Kranzler HR**, Gelernter J. *S100A10* identified in a genome-wide gene-by-cannabis dependence interaction analysis of risky sexual behaviors. *Journal of Psychiatry and Neuroscience*, 42:252-261, 2017. (PMCID: PMC5487272)
394. Douglas-Newman K, Smith RV, Spiers MV, Pond T, **Kranzler HR**. Effects of recent alcohol consumption on neurocognitive performance in HIV+ individuals, *Addictive Disorders & Their Treatment*, 16:95-107, 2017. (PMCID: PMC5654614)
395. **Kranzler HR**, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E. Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? *Addiction* 112:2086-2094, 2017. (PMCID: PMC5650957)
396. Polimanti R, Zhao H, Farrer L, **Kranzler HR**, Gelernter J. Ancestry-specific and sex-specific risk alleles identified in a genome-wide gene-by-alcohol dependence interaction study of risky sexual behaviors. *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 174B:846–853, 2017.
397. Polimanti, Amstadter AB, Stein MB, Almli LM, Baker DG, Bierut LJ, Bradley B, Farrer, LA, Johnson EO, King A, **Kranzler H**, Maihofer AX, Rice JP, Roberts AL, Saccone NL, Zhao H, Liberzon I, Ressler KJ, Nievergelt CM, Koenen KC, Gelernter J for The Psychiatric Genomics Consortium Post-Traumatic Stress Disorder Workgroup. A putative causal relationship between genetically determined female body shape and posttraumatic stress disorder. *Genome Medicine* 9:99, 2017. (PMCID: PMC5702961)

398. Zhou H, Polimanti R, Yang B-Z, Wang Q, Han S, Sherva R, Nunez Y, Zhao H, Farrer L, **Kranzler HR**, Gelernter J. Genetic risk variants associated with comorbid alcohol dependence and major depression. *JAMA Psychiatry* 74:1234-1241, 2017.
399. Lieberman L, **Kranzler HR**, Levine E, Covault J. Examining the effects of alcohol on GABA_A receptor mRNA expression and function in neural cultures generated from control and alcohol dependent donor induced pluripotent stem cells. *Alcohol* 66:45-53, 2018. (PMCID: PMC5743620)
400. Tielbeek JJ, Johansson A, Polderman TJC, Rautiainen M-R, Jansen P, Taylor M, Tong X, Lu Q, Burt AS, Tiemeier H, Viding E, Plomin R, Martin NG, Heath AC, Madden PAF, Montgomery G, Beaver KM, Waldman I, Gelernter J, **Kranzler HR**, Farrer LA, Munafò M, Paunio T, Mous SE, Pappa I, de Leeuw C, Hammerschlag AR, Salvatore JE, Aliev F, Bigdeli TB, COGA Consortium, Dick D, Faraone SV, Popma A, Medland SE, Posthuma D. Genome-wide association studies of a broad spectrum of antisocial behaviour. *JAMA Psychiatry*, 74:1242-1250, 2017.
401. Andersen AM, Pietrzak RH, **Kranzler HR**, Ma L, Zhou H, Liu X, Kramer J, Kuperman S, Edenberg HK, John I. Nurnberger JI, Rice JP, Tischfield JA, Goate A, Foroud TM, Meyers JL, Porjesz B, Dick DM, Hesselbrock V, Boerwinkle E, Southwick SM, Krystal JH, Weissman MM, Levinson DF, Potash JB, Gelernter J, Han S. Shared genetic basis of alcohol dependence and major depressive disorder: Evidence from polygenic risk score analysis. *JAMA Psychiatry*, 74:1153-1160, 2017. (PMCID: PMC5710224)
402. Polimanti R, Kaufman J, Zhao H, **Kranzler HR**, Ursano RJ, Kessler RC, Gelernter J, Stein MB. A genome-wide gene-by-trauma interaction study of alcohol misuse in two independent cohorts identifies *PRKG1* as a risk locus. *Molecular Psychiatry* 23(1):154-160, 2018 (PMCID: PMC5589475)
403. Polimanti R, Kaufman J, Zhao H, **Kranzler HR**, Ursano R, Kessler R, Stein M, Gelernter J. Trauma exposure interacts with the genetic risk of bipolar disorder in alcohol misuse of US soldiers. *Acta Psychiatrica Scandinavica*, 137:148-156, 2018.
404. Lu J, Sun J, Wang X, **Kranzler HR**, Gelernter J, Bi J. Collaborative phenotype inference from comorbid substance use disorders and genotypes. *Proceedings of the IEEE International Conference on Bioinformatics and Biomedicine*. 2017:392-397. (PMCID: PMC5947969)
405. Curtis BL, Lookatch SJ, Ramo DE, McKay JR, Feinn RS, **Kranzler HR**. Meta-analysis of the association of alcohol-related social media use with alcohol consumption and alcohol-related problems in adolescents and young adults. *Alcoholism: Clinical and Experimental Research*. 42:978-986, 2018. (PMCID: PMC5984178)
406. Zhang H, Zhou H, Lencz T, Farrer LA, **Kranzler HR**, Gelernter J. Genome-wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*. 177B:511-519, 2018. (PMCID: PMC6110090)
407. Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-Koch AE, Baker DG, Beckham JC, Bierut LJ, Bisson J, Bradley B, Chen CY, Dalvie S, Farrer LA, Galea S, Garrett ME, Gelernter JE, Guffanti G, Hauser MA, Johnson EO, Kessler RC, Kimbrel NA, King A, Koen N, **Kranzler HR**, Logue MW, Maihofer AX, Martin

AR, Miller MW, Morey RA, Nugent NR, Rice JP, Ripke S, Roberts AL, Saccone NL, Smoller JW, Stein DJ, Stein MB, Sumner JA, Uddin M, Ursano RJ, Wildman DE, Yehuda R, Zhao H, Daly MJ, Liberzon I, Ressler KJ, Nievergelt CM, Koenen KC. Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. *Molecular Psychiatry*. 23:666-673, 2018. (PMCID: PMC5696105)

408. Morley K, **Kranzler HR**, Luquin N, Baillie A, Shanahan M, Trent R, Teesson M, Haber P. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). *Trials*, 19:443, 2018. (PMCID: PMC6097336)
409. Hancock DB, Guo Y, Reginsson GW, Gaddis NC, Lutz SM, Sherva R, Loukola A, Minica C, Markunas CA, Han Y, Young KA, Gudbjartsson DF, Gu F, McNeil DW, Qaiser B, Glasheen C, Olson S, Landi MT, Madden PAF, Farrer LA, Vink J, Saccone NL, Neale MC, **Kranzler HR**, McKay J, Hung RJ, Amos CI, Marazita ML, Boomsma DI, Baker TB, Gelernter J, Kaprio J, Caporaso NE, Thorgeirsson TE, Hokanson JE, Bierut LJ, Stefansson K, Johnson EO. Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. *Molecular Psychiatry*, 2017 Oct 3. doi: 10.1038/mp.2017.193. [Epub ahead of print]
410. Agrawal A, Chou Y-L, Carey C, Baranger D, Zhang B, Sherva R, Wetherill L, Kapoor M, Wang JC, Bertelsen S, Anokhin A, Hesselbrock V, Kramer J, Lynskey MT, Meyers JL, Nurnberger JI Jr, Rice JP, Tischfield J, Bierut LJ, Degenhardt L, Farrer LA, Gelernter J, Hariri A, Heath, **Kranzler HR**, Madden PAF, Martin NG, Montgomery G, Porjesz B, Wang T, Whitfield JB, Edenberg HJ, Foroud T, Goate AM, Bogdan R, Nelson E. Genomewide association study identifies a novel locus for cannabis dependence. *Molecular Psychiatry, Mol Psychiatry*. 2017 Nov 7. doi: 10.1038/mp.2017.200. [Epub ahead of print]
411. Cheng Z, Zhou H, Sherva R, Farrer L, **Kranzler HR**, Gelernter J. Genome-wide association study identifies a regulatory variant of RGMA associated with opioid dependence in European Americans. *Biological Psychiatry*, 2018 Jan 11. pii: S0006-3223(18)30028-3. doi: 10.1016/j.biopsych.2017.12.016. [Epub ahead of print]
412. Montalvo-Ortiz J, Zhou H, D'Andrea I, Maroteaux L, Lori A, Smith A, Ressler K, Nunez Y, Farrer L, Zhao H, **Kranzler HR**, Gelernter J. Translational studies support a role for serotonin 2B receptor gene (HTR2B) in aggression-related cannabis response. *Molecular Psychiatry*. 2018 Jun 6. doi: 10.1038/s41380-018-0077-6. [Epub ahead of print]
413. Witkiewitz K, Votaw V, Vowles K, **Kranzler HR**. Opioid misuse as a predictor of alcohol treatment outcomes in the COMBINE Study: Mediation by medication adherence. *Alcoholism: Clinical and Experimental Research*. 42:1249-1259, 2018 (PMCID: PMC6063524).
414. DeMartini KS, Foster DW, Corbin WR, Fucito LM, Romano D, Leeman RF, **Kranzler HR**, O'Malley SS. Drinking goals and attainment in a naltrexone trial of young adult heavy drinkers, *Journal of Consulting and Clinical Psychology*, 86:765-774, 2018.

415. **Kranzler HR**, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: A review. *JAMA*, 320:815-824, 2018.
416. Justice AC, Smith RV, Tate JP, McGinnis K, Xu K, Becker WC, Lee K-Y, Lynch K, Sun N, Concato J, Fiellin DA, Zhao H, Gelernter J, **Kranzler HR** on behalf of the VA Million Veteran Program. AUDIT-C and ICD Codes as phenotypes for harmful alcohol use: Association with *ADH1B* polymorphisms in two U.S. populations. *Addiction*. 2018 Jul 4. doi: 10.1111/add.14374. [Epub ahead of print]
417. Minică C, Verweij K, van der Most P, Mbarek, Bernard M, van Eijk K, Lind P, Liu M, Maciejewski D, Palviainen T, Sánchez-Mora C, Sherva R, Taylor M, Walters R, Abdellaoui A, Bigdeli T, Branje S, Brown S, Casas M, Corley, R, Davey Smith G, Davies G, Ehli E, Farrer L, Fedko I, Garcia-Martínez I, Gordon S, Hartman C, Heath A, Hickie I, Hickman, M, Hopfer C, Hottenga JJ.; Kahn R, Kaprio J, Korhonen T, **Kranzler H**; Krauter K, van Lier P, Madden P, Medland S, Neale M, Meeus W, Montgomery G, Nolte I, Oldehinkel A, Pausova Z, Ramos-Quiroga J, Richarte V, Rose R, Shin J, Stallings M, Wall T, Ware J, Wright M, Zhao H, Koot H, Paus T, Hewitt J, Ribasés M, Loukola A, Boks M, Snieder H, Munafò M, Gelernter J, Boomsma D, Martin N, Gillespie N, Vink J, Derks E. Genome-wide association meta-analysis of age at first cannabis use. *Addiction*, 2018 Jul 13. doi: 10.1111/add.14368. [Epub ahead of print]
418. Chakravorty S, Smith RV, Perlis ML, Grandner MA, **Kranzler HR**. Circadian pattern of deaths due to suicide in intoxicated alcohol-dependent individuals. *Journal of Clinical Psychiatry*, in press.
419. Zhou H, Cheng Z, Bass N, Krystal JH, Farrer LH, **Kranzler HR**, Gelernter J. Genome-wide association study identifies glutamate ionotropic receptor *GRIA4* as a risk gene for comorbid nicotine dependence and major depression. *Translational Psychiatry*, in press.
420. McGinnis KA, Justice AC, Tate JP, Becker WC, Tindle H, Concato J, Gelernter J, **Kranzler HR**, Li B, Zhang X, Zhao H, Crothers K, Xu K for the VACS Project Group. Using DNA methylation to validate an electronic medical record phenotype for smoking. *Addiction Biology*, in press.
421. Falk DE, O'Malley SS, Witkiewitz K, Anton RF, Litten RZ, Slater M, **Kranzler HR**, Mann KF, Hasin DS, Johnson B, Meulien D, Ryan M, Fertig J, and members of the ACTIVE Workgroup. Reductions in drinking risk level as outcomes in alcohol pharmacotherapy trials. *JAMA Psychiatry*, in press.
422. Walters RK, Adams MJ, Adkins AE, Aliev F, Bacanu S-A, Batzler A, Bertelsen S, Biernacka JM, Bigdeli TB, Chen L-S, Clarke T-K, Chou Y-L, Degenhardt F, Docherty AR, Fontanillas P, Foo J, Fox L, Frank J, Giegling I, Gordon S, Hack LM, Hartmann AM, Hartz SM, Heilmann-Heimbach S, Herms S, Hodgkinson C, Hoffmann P, Hottenga JJ, Kennedy MA, Alanne-Kinnunen M, Konte B, Lahti J, Lahti-Pulkkinen M, Ligthart L, Loukola A, Maher BS, Mbarek H, McIntosh AM, McQueen MB, Milaneschi Y, Palviainen T, Pearson JF, Peterson RE, Polimanti R, Ripatti S, Ryu E, Saccone NL, Salvatore JE, Roige SS, Melanie Schwandt M, Sherva S, Streit F, Strohmaier J, Thomas N, Wang J-C, Webb BT, Wedow R, Wetherill L, Wills AT, 23andMe Research Team #13, Boardman JD, Chen D, Choi D-S, Copeland WE, Culverhouse RC, Dahmen N, Degenhardt L, Domingue BW, Elson SL, Frye M, Gabel

W, Ising M, Johnson EC, Keyes M, Kiefer F, Kramer J, Kuperman S, Lucae S, Lynskey MT, Maier W, Mann K, Männistö S, McClintik JN, Meyers JL, Müller-Myhsok B, Nurnberger JI, Palotie A, Preuss U, Rääkkönen K, Reynolds MD, Ridinger M, Scherbaum N, Schuckit M, Soyka M, Treutlein J, Witt S, Wodarz N, Zill P, Adkins DE, Boden JM, Boomsma D, Bierut LJ, Brown SA, Bucholz KB, Cichon S, EJ Costello, de Wit H, Diazgranados N, Dick DM, Eriksson JG, Farrer LA, Foroud TM, Gillespie NA, Goate AM, Goldman D, Gruzca RA, Hancock DB, Harris KM, Heath AC, Hesselbrock V, Hewitt JK, Hopfer C, Horwood J, Iacono I, Johnson EO, Kaprio JA, Karpyak V, Kendler KS, **Kranzler HR**, Krauter K, Lichtenstein P, Lind PA, McGue M, MacKillop J, Madden PAF, Maes H, Magnusson P, Martin NG, Medland SE, Montgomery GW, Nelson EC, Nöthen MM, Palmer AA, Pedersen N, Penninx B, Porjesz B, Rice JP, Rietschel M, Riley BP, Rose R, Rujescu D, Shen P-H, Silberg J, Stallings MC, Tarter RE, Vanyukov MM, Vrieze S, Wall TL, Whitfield JB, Zhao Z, Neale B, Gelernter J, Edenberg HJ, Agrawal A. Trans-ancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nature Neuroscience*, in press.

423. Knox J, Wall M, Witkiewitz K, **Kranzler HR**, Falk D, Litten R, Mann K, O'Malley S, Scodes S, Anton R, Hasin DS, for the Alcohol Clinical Trials (ACTIVE) Workgroup. Reduction in non-abstinent WHO drinking risk levels and change in risk for liver disease and positive AUDIT-C scores: Prospective 3-year follow-up results in the US general population. *Alcoholism: Clinical and Experimental Research*, in press.
424. Smith AH, Olsen D, Ovesen PL, Yeo S, Jensen KP, Diazgranados N, Zhao H, Farrer LA, Goldman D, Glerup S, **Kranzler HR**, Nykjær A, Gelernter J. Risk locus identification ties alcohol withdrawal symptoms to *SORCS2*. *Alcoholism: Clinical and Experimental Research*, in press.
425. Witkiewitz K, **Kranzler HR**, Hallgren KA, Hasin DS, Mann KF, Falk DE, Litten RZ, O'Malley SS, Anton RF for the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup. Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder, *Alcoholism: Clinical and Experimental Research*, in press.
426. Lieberman R, Clinton K, Levine ES, **Kranzler HR**, Covault J. Molecular correlates of topiramate and *GRIK1* rs2832407 genotype in iPSC-derived neural cells, in revision.
427. Xiang B, Yang B-Z, Zhou H, **Kranzler HR**, Gelernter J. GWAS and network analysis of co-occurring nicotine and alcohol dependence identifies significantly associated alleles and network, in revision.
428. Otowa T, Musci R, Han S, Benke K, Maher BS, Adkins DE, Aggen SH, Uhl GR, Eaton WW, Ialongo N, Gelernter J, **Kranzler HR**, van den Oord EJ, Hettema JM. Genome-wide association study of depressive and anxiety disorders in African-Americans, in review.
429. Jensen KP, Han S, Stein MB, Liu X, Zhao H, **Kranzler HR**, Gelernter J. Whole exome sequencing identifies rare variants in *MLL2* associated with anxiety disorder risk, in review.

430. Wang Q, Zhao H, **Kranzler HR**, Gelernter J. PTPRD and childhood adversity interactive effect on PTSD risk: a genome-wide gene-environment interaction analysis, in review.
431. Montalvo-Ortiz JL, Sherva R, **Kranzler HR**, Almasy L, Koesterer R, Zhao H, Farrer LA, Gelernter J. Genome-wide association study of smoking quantity: Identification of novel risk loci in both African- and European-Americans, in review.
432. Marees AT, Gamazon ER, Vorspan F, Fingal J, van den Brink W, Verweij KJH, **Kranzler HR**, Sherva R, Farrer L, International Cannabis Consortium, Gelernter J, Derks EM. Post-GWAS analysis of eight substance use traits improves the identification and functional interpretation of genetic risk loci, in review.
433. Chen J, Loukola A, Gillepie N, Peterson R, Jia P, Riley B, Maes H, Dick DM, Kendler KS, Damaj MI, Miles MF, Zhao Z, Li MD, Vink JM, Minica CC, Willemsen G, Boomsma DI, Qaiser B, Madden PAF, Korhonen T, Gelernter J, **Kranzler HR**, Sherva R, Farrer L, Maher B, Vanyukov M, Taylor M, Ware JJ, Munafò MR, Lutz SM, Hokanson JE, Gu F, Landi MT, Caporaso NE, Hancock DB, Gaddis NC, Baker TB, Bierut LJ, Johnson EO, Chenoweth M, Lerman C, Tyndale R, Kaprio J, Chen X. Genome-wide meta-analysis of FTND and TTFC phenotypes, in review.
434. Delgado MK, Shofer S, Wetherill R, Curtis B, Hemmons J, Spencer E, Branas C, Wiebe D, **Kranzler HR**. Accuracy of smartphone-paired alcohol breath testing devices: A laboratory validation study, in review.
435. Gelernter J, Sun N, Polimanti R, Pietrzak R, Lu Q, Hu Y, Li B, Chen Q, Radhakrishnan K, Aslan M, Cheung KH, Li Y, Rajeevan N, Sayward F, Harrington K, Cho K, Honerlaw J, Pyarajan S, Lencz T, Quaden R, Gaziano JM, **Kranzler HR**, Concato J, Zhao H, Stein MB, on behalf of the Department of Veterans Affairs Cooperative Studies Program (#575B) and Million Veteran Program. GWAS of maximum habitual alcohol intake in >140,000 US European- and African-American veterans yields novel risk loci, in review.
436. Jensen KP, Lieberman R, **Kranzler HR**, Gelernter J, Covault J. Alcohol-responsive genes identified in human iPSC-derived neural cultures, in review.
437. Levey DF, Polimanti R, Cheng Z, Zhou H, Nuñez YZ, Jain S, He F, Sun X, Ursano RJ, Kessler RC, Smoller JW, Stein MB, **Kranzler HR**, Gelernter J. Genetic associations with suicide attempt severity, in review.
438. **Kranzler HR**, Zhou H, Kember RL, Smith RV, Justice AC, Damrauer S, Rader S, Regeneron Genetics Center Research Team, Cheng Z, Tate JP, Becker WC, Concato J, Xu K, Polimanti R, Zhao H, Gelernter J Mon behalf of the VA Million Veteran Program. Genome-wide association study of alcohol consumption and use disorder in multiple populations (N = 274,424), in review.
439. Lookatch SJ, Smith RV, McKay JR, Gelernter J, **Kranzler HR**. Impact of recent childbirth on healthcare utilization in substance dependent adults, in review.
440. Sun J, **Kranzler HR**, Gelernter J, Bi J. A genome-wide association study of cocaine use disorder: Accounting for phenotypic heterogeneity and gene-environment interaction, in review.

441. Cheng Z, Phokaew C, Chou Y-L, Lai D, Meyers J, Agrawal A, Farrer L, **Kranzler HR**, Gelernter J. A regulatory variant of *CHRM3* is associated with cannabis-induced hallucinations in European Americans, in review.
442. Knox J, Wall M, Witkiewitz K, **Kranzler HR**, Falk D, Litten R, Mann K, O'Malley SS, Scodes J, Anton R, Hasin DS – for the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population, in review.
443. Oncken C, Dornelas E, Kuo C-L, Sankey H, **Kranzler HR**, Mead EL, Thurlow S. Randomized trial of nicotine inhaler for pregnant smokers, in review.
444. Lu J, Sun J, Wang X, **Kranzler H**, Gelernter J, Bi J. Inferring phenotypes from substance use via collaborative matrix completion, in review.
445. Rosato AJ, Chen X, Tanaka Y, Farrer LA, **Kranzler HR**, Henderson DC, Gelernter J, Zhang H. Salivary microRNAs identified by small RNA sequencing and machine learning as potential biomarkers of alcohol dependence, in review.
446. Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, **Kranzler HR**, Becker WC, for the VACS Project Team. Patterns and correlates of prescription opioid receipt: an 18-year observational cohort study, in review.

Edited Volumes

1. Meyer RE, **Kranzler HR** (Eds.), Neurobiology of Alcoholism, *Clinical Neuroscience*: 3:141-188, 1995.
2. **Kranzler HR**, Rounsaville BJ (Eds.), *Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders*, New York: Marcel Dekker, 1998.
3. Carson-DeWitt R, Carroll KM, Fagan J, **Kranzler HR**, Kuhar MJ (Eds.), *Encyclopedia of Drugs, Alcohol and Addictive Behavior*, 2nd ed., New York: Macmillan, 2001.
4. **Kranzler HR** (Ed.), Neurobiology, Diagnosis and Treatment of Alcohol Dependence. *American Journal on Addictions* (Suppl 1), 2003.
5. **Kranzler HR**, Tinsley JA (Eds.), *Dual Diagnosis and Treatment: Substance Abuse and Comorbid Psychiatric Disorders*, 2nd Ed., New York: Marcel Dekker, 2004.
6. **Kranzler HR**, Ciraulo D (Eds), *Clinical Manual of Addiction Psychopharmacology*, Washington, DC: American Psychiatric Press, Inc., 2005.
7. **Kranzler HR**, Martinelli A (Eds), Alcohol and Other Drugs. *Alcohol Research and Health*, Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 32:2 (NIH Publication No. 08-3466), 2008.
8. Korsmeyer P, **Kranzler HR**, Berridge V, Campbell N, Carroll KM, Hasin D, Kuhar MJ, Wish E (Eds.), *Encyclopedia of Drugs, Alcohol and Addictive Behavior*, 3rd ed., New York: Macmillan, 2009.
9. **Kranzler HR**, Ciraulo D, Zindel L (Eds), *Clinical Manual of Addiction*

Psychopharmacology, 2nd ed., Washington, DC: American Psychiatric Press, Inc., 2014.

Book Chapters, Conference Proceedings, Case Reports, Letters, and Other Publications

1. **Kranzler HR**, Vayda AP. Disruption of iodine supply as a result of development: Endemic goiter and cretinism. In Singh JS and Gopal B. (Eds.). *Glimpses of Ecology*, pp. 11-518. International Scientific Publications: Jaipur, India, 1978.
2. **Kranzler HR**. Review of *Current Perspectives in Cultural Psychiatry*. Foulks EF, Wintrob RM, Westermeyer J and Favazza AR (Eds.). *Medical Anthropology Newsletter*, 12:13-14, 1981.
3. Feder HM, Leicher CR, Bourbeau PO, **Kranzler H**, Deutsch L. A New England case of infant botulism. *The Journal of Infectious Disease*, 149:482-483 (Ltr. Ed.), 1984.
4. **Kranzler HR**. Maprotiline and myoclonus. *Journal of Clinical Psychiatry*, 46:503 (Ltr. Ed.), 1985.
5. **Kranzler HR**. A practitioner's guide to the medical risks of social drinking. *Resident and Staff Physician*, 33:80-85, 1987.
6. **Kranzler HR**. Psychosocial issues concerning a pregnant adolescent with Hodgkin's disease. *Journal of Psychosocial Oncology*, 5:83-89, 1987.
7. Wong SHY, **Kranzler HR**. Monitoring imipramine/desipramine blood concentrations. *Drug Monitoring and Toxicology* 9:1-7, 1988.
8. **Kranzler HR**, Liebowitz, N. Depression and anxiety in substance abuse: Clinical implications. In Frazier, S. (Ed.). *Anxiety and Depression, Medical Clinics of North America* 72:867-885, 1988. Philadelphia: Williams and Wilkins.
9. **Kranzler HR**, Babor TF. Review of *Mental Disorders: Alcohol-and Drug-Related Problems: International Perspectives on Their Diagnosis and Classification*. (W.H.O. Regional Office for Europe). *Journal of Studies on Alcohol*, 49:384-385, 1988.
10. **Kranzler HR**. Secondary depression: Treatment and outcome. *Journal of Clinical Psychiatry*, 49:370 (Ltr. Ed.), 1988.
11. **Kranzler, HR.**, Cardoni, A. Sodium chloride treatment of antidepressant-induced orthostatic hypotension. *Journal of Clinical Psychiatry*, 49:366-368, 1988.
12. **Kranzler HR**. Buspirone treatment of an adolescent with overanxious disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 27:789-790, 1988.
13. El Mallakh R, Donaldson J, **Kranzler HR**, Racy A. Phenothiazine-associated lupus anticoagulant: A case report and literature review. *Psychosomatics*, 29:109-113, 1988.
14. **Kranzler HR**, Shah PJ. Atypical koro. *British Journal of Psychiatry*, 152:579-580 (Ltr. Ed.), 1988.
15. **Kranzler HR**, Gorelick, D.A. Serotonin uptake inhibitors: Ideal pharmacotherapy for relapse prevention? In Waahlberg, R. (Ed.). *Proceedings of the 35th International*

- Congress on Alcoholism and Drug Dependence*, Vol. 2, pp. 661-670, Oslo: National Directorate for the Prevention of Alcohol and Drug Problems, Norway, 1989.
16. Rounsaville B, **Kranzler HR**. The DSM-III-R diagnosis of alcoholism. In Tasman, A. (Ed.). *Annual Review of Psychiatry*, Vol. 8, pp 323-340, Washington, D.C.: American Psychiatric Press, 1989.
 17. **Kranzler HR**, Orrok, B. The pharmacotherapy of alcoholism. In Tasman, A. (Ed.). *Annual Review of Psychiatry*, Vol. 8, pp 359-379, Washington, D.C.: American Psychiatric Press, 1989.
 18. **Kranzler HR**. Buspirone treatment of anxiety in a patient dependent on alprazolam. *Journal of Clinical Psychopharmacology*, 9:153 (Ltr. Ed.), 1989.
 19. **Kranzler HR**, Meyer, R.E. An open trial of buspirone in alcoholics. *Journal of Clinical Psychopharmacology*, 9:379-380 (Ltr. Ed.), 1989.
 20. Meyer RE, **Kranzler HR**. Alcohol abuse/dependence and co-morbid anxiety and depression. In Maser JD and Cloninger CR (Eds.) *Comorbidity in Anxiety and Mood Disorders*, Washington, D.C.: American Psychiatric Press, pp. 283-292, 1990.
 21. Liebowitz NR, **Kranzler HR**, Meyer, R.E. Pharmacologic approaches to alcoholism treatment. *Alcohol Health and Research World* 14:144-153, 1990.
 22. **Kranzler HR**, Babor, T.F. The identification and treatment of alcohol abuse/dependence. *Annals of Clinical Psychiatry* 2:229-238, 1990.
 23. Jaffe JH, **Kranzler HR**, Ciraulo D. Drugs used in the treatment of alcoholism. In JH Mendelson and NK Mello (Eds.). *Medical Diagnosis and Treatment of Alcoholism*, New York: McGraw Hill, pp. 421-461, 1992.
 24. **Kranzler HR**, Del Boca F, Korner P, Brown J. Fluvoxamine is poorly tolerated by alcoholics. In Naranjo CA, and Sellers EM (Eds.). *Novel Pharmacological Interventions for Alcoholism*. New York: Springer-Verlag, pp. 304-306, 1992.
 25. Kadden R, **Kranzler HR**. Alcohol and drug abuse treatment at the University of Connecticut Health Center. *British Journal of Addiction* 87:521-526, 1992.
 26. **Kranzler HR**, Ginther L, Ttofi C. Intra-gastric infusion of ethanol by alcoholics after surgery for head and neck cancer. *American Journal on Addictions*, 1:83-85, 1992.
 27. **Kranzler HR**, Bauer LO. Cue reactivity as a method to screen medications for cocaine dependence. *Addictive Behaviors*, 18:599-600 (Ltr. Ed.), 1993.
 28. Babor TF, Grant M, Acuda W, Burns FH, Campillo C, Del Boca FK, Hodgson R, Ivanets NN, Lukomskya M, Machona M, Rollnick S, Resnick R, Saunders JB, Skutle A, Connor K, Ernberg G, **Kranzler H**, Lauerman R, McRee B. Randomized clinical trial of brief interventions in primary healthcare – summary of a WHO project. *Addiction* 89:657-660, 1994.
 29. West R, **Kranzler HR**. Craving for cigarettes and psychoactive drugs. In Warburton D (Ed.), *Addiction Controversies*, London: Harwood Academic Publishers, 1992.
 30. Brown J, Babor TF, Litt MD, **Kranzler HR**. The Type A/Type B distinction: Subtyping alcoholics according to indicators of vulnerability and severity. In Babor

- TF, Hesselbrock V, Meyer RE, Shoemaker W (Eds.), *Types of Alcoholics: Evidence from Clinical, Experimental, and Genetic Research. Annals of the New York Academy of Sciences* 708:23-33, 1994.
31. **Kranzler HR**, Jaffe JH. Pharmacologic therapies for alcoholism. In Miller N (Ed.), *Principles of Addiction Medicine*. Chevy Chase, MD: American Society of Addiction Medicine, 1994.
 32. **Kranzler HR**, McLellan AT, Bohn M. Pharmacotherapies for alcoholism: Theoretical and methodologic perspectives. In Kranzler HR (Ed.), *The Pharmacology of Alcohol Abuse*, New York: Springer-Verlag, pp. 513-537, 1995.
 33. **Kranzler HR**. The pharmacology of alcohol abuse: An introduction. In Kranzler HR (Ed.), *The Pharmacology of Alcohol Abuse*, New York: Springer-Verlag, pp. 1-10, 1995.
 34. Meza E, **Kranzler HR**. Closing the gap between alcoholism research and practice: The case for pharmacotherapy. *Psychiatric Services*, 47:917-920, 1996.
 35. **Kranzler HR**. Evaluation and treatment of anxiety symptoms and disorders in alcoholics. *Journal of Clinical Psychiatry* 57:15-21, 1996.
 36. **Kranzler HR**, Higgins-Biddle J. Guidelines for identification and intervention with problem drinkers in the primary-care setting. *Primary Psychiatry*, 3:71-78, 1996.
 37. **Kranzler HR**, Moore PJ, Babor TF. Alcohol use disorders. In Taylor DH, Tasman A, Kay J, Lieberman JA. (Eds.), *Psychiatry: Self-Assessment and Review*, Philadelphia: W.B. Saunders, pp. 116-118, 1997.
 38. **Kranzler HR**, Moore PJ, Babor TF. Alcohol use disorders. In Tasman A, Kay J, Lieberman JA. (Eds.), *Psychiatry*, Philadelphia: W.B. Saunders, pp. 755-778, 1997.
 39. **Kranzler HR**, Evaluation and treatment of problem drinking. In Rakel RE. (Ed.), *Conn's Current Therapy*. Philadelphia: W.B. Saunders, pp. 1139-1142, 1997.
 40. **Kranzler HR**, Mason, BJ, Pettinati HM, Anton RF: Methodological issues in pharmacotherapy trials with alcoholics. In Hertzman M, and Feltner D. (Eds.), *The Handbook of Psychopharmacology Trials*, New York: New York University Press, pp. 213-245, 1997.
 41. Hersh D, **Kranzler HR**, Meyer RE. Persistent delirium following the cessation of heavy alcohol consumption: Diagnostic and treatment implications. *American Journal of Psychiatry*, 154:846-851, 1997.
 42. **Kranzler HR**, Babor TF. Is the medication bottle half full or half empty? *Addiction*, 92:951-953, 1997.
 43. **Kranzler HR**. Treatment of alcohol dependence. *Liver Transplantation and Surgery*, 3:311-321, 1997.
 44. **Kranzler HR**, Mason BJ, Modesto-Lowe V. Prevalence, diagnosis, and treatment of comorbid mood disorders and alcoholism. In Kranzler HR and Rounsaville BJ. (Eds.), *Dual Diagnosis: Substance Abuse and Comorbid Medical and Psychiatric Disorders*, New York: Marcel Dekker, pp. 107-136, 1998.

45. **Kranzler HR**, Jaffe, J.H. Pharmacologic Therapies for Alcoholism. In Graham AW, Schultz TK. (Eds.), *Principles of Addiction Medicine*, 2nd Edition, Chevy Chase, MD: American Society of Addiction Medicine, pp. 501-516, 1998.
46. **Kranzler HR**, Amin H, Modesto-Lowe V, Oncken C. Pharmacologic treatments for drug and alcohol dependence. In Miller NS, Swift RM. (Eds.), *Psychiatric Clinics of North America*, Philadelphia: Williams & Wilkins, 22:401-423, 1999. (PMID: 10385941)
47. Modesto-Lowe V, **Kranzler HR**. Diagnosis and treatment of alcohol-dependent patients with comorbid psychiatric disorders. *Alcohol Research & Health*, 23:144-149, 1999.
48. **Kranzler HR**. Medications for alcohol dependence: New vistas. *JAMA*, 284:1016-1017, 2000. (Editorial)
49. **Kranzler HR**. Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. *Alcohol and Alcoholism*, 35: 537-547, 2000.
50. Gelernter J, **Kranzler HR**. Genetic variation and drug dependence risk factors. In Lerer B (Ed.), *Pharmacogenetics of Psychotropic Drugs*, Cambridge University Press, pp. 372-387, 2002.
51. Sandstrom KA, **Kranzler HR**. Sweet taste preference and alcohol dependence (reply). *American Journal of Psychiatry*, 159:498, 2002.
52. Oncken C, **Kranzler H**, Campbell W. The effect of cigarette smoking on fetal heart rate characteristics (reply). *Obstetrics and Gynecology*, 100:829, 2002
53. Babor TF, **Kranzler HR**, Hernandez-Avila CA, Ungemack, J. Alcohol use disorders. In Tasman A, Kay J, Lieberman JA. (Eds.), *Psychiatry*, Philadelphia: W.B. Saunders, 2nd edition, pp. 936-972, 2003.
54. **Kranzler HR**. Introduction. In Kranzler HR. (Ed.), *Neurobiology, Diagnosis and Treatment of Alcohol Dependence*, *American Journal on Addictions*, 12(suppl. 1): S1-S2, 2003.
55. **Kranzler HR**, Rosenthal RN. Dual diagnosis: Alcoholism and co-morbid psychiatric disorders, In Kranzler HR. (Ed.), *Neurobiology, Diagnosis and Treatment of Alcohol Dependence*, *American Journal on Addictions*, 12(suppl. 1): S26-S40, 2003.
56. **Kranzler HR**, Jaffe JH. Pharmacologic Interventions for Alcoholism. In Graham AW, Mayo-Smith MF, Ries RK, Schultz TK (Eds.), *Principles of Addiction Medicine*, 3rd Edition, Chevy Chase, MD: American Society of Addiction Medicine, pp. 701-719, 2003.
57. Oncken CA, **Kranzler HR**. Pharmacotherapies for smoking cessation during pregnancy. *Drug and Alcohol Review*, 22:191-202, 2003.
58. Kosten TR, **Kranzler HR**. What will we learn from the FDA clinical trials process and what will we still want to know about immunotherapies and depot medications to treat drug dependence? In Harwood, HJ, Myers TG (Eds.), *New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions*, Washington, D.C.: The

National Academies Press, pp. 98-124, 2004.

59. **Kranzler HR.** Preface to *Treatment of Alcohol and Drug Abuse—An Evidence-Based Review*, Berglund M, Johnsson E, Thelander S (Eds.), Weinheim: Wiley-VCH, 2004.
60. Modesto-Lowe V, Pierucci-Lagha A, **Kranzler HR.** Substance abuse and mood disorders: Prevalence, diagnosis, and treatment. In Kranzler HR, Tinsley JA (Eds.), *Dual Diagnosis and Psychiatric Treatment: Substance Abuse and Comorbid Disorders*, 2nd Ed., New York: Marcel Dekker, 2004, pp. 157-191.
61. **Kranzler HR,** Tennen H. How to measure relapse in humans. In Spanagel R, Mann K (Eds.), *Drugs for Relapse Prevention of Alcoholism*, Basel: Birkhauser Verlag, 2005, pp. 23-39.
62. **Kranzler H.** New treatment strategies for alcohol dependence. In Kraus MI (Ed.) 2004 update on addiction medicine/psychiatry in the state of Connecticut. *Connecticut Medicine* 69:224, 2005.
63. **Kranzler HR,** Ciraulo D. Pharmacotherapy for alcoholism. In **Kranzler HR,** Ciraulo D (Eds), *Clinical Manual of Addiction Psychopharmacology*, Washington, DC: American Psychiatric Press, Inc., 2005, pp. 1-54.
64. Luo X, Gelernter J, Zhao H, **Kranzler HR.** Response to Dr. Kopke's comments on haplotypes at the OPRM1 locus. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 135B:102, 2005
65. Garbutt JC, **Kranzler HR,** O'Malley SS, Gastfriend DR, Silverman BL, Loewy JW, Ehrich EW, Pettinati HM. Naltrexone treatment for alcohol dependency—Reply. *JAMA*, 294:900, 2005.
66. **Kranzler, HR.** Medications to treat heavy drinking: Are we there yet? *Addiction*, 101:153-154, 2006.
67. **Kranzler HR,** Koob G, Gastfriend D, Swift RM, Willenbring ML. Advances in the pharmacotherapy of alcoholism: Challenging misconceptions. *Alcoholism: Clinical and Experimental Research*, 30:272-281, 2006.
68. **Kranzler HR.** Evidence-based treatments for alcohol dependence—New results and new questions. *JAMA*, 295:2075-2076, 2006.
69. **Kranzler HR.** Extended-release intramuscular naltrexone: a viewpoint. *Drugs*. 66:1752-1754, 2006.
70. Gelernter J, **Kranzler HR.** Genetics of substance dependence. In Deng H-W, Shen H, Liu Y-J, Hu H (Eds), *Current Topics in Human Genetics: Studies in Complex Diseases*, World Scientific Publishing Co., 2007, pp. 865-882.
71. Johnson BA, Anton RF, **Kranzler HR,** Mann K, O'Malley SS, Swift R. Topiramate treatment of alcohol dependence—Reply. *JAMA*, 299: 406-407, 2008.
72. Gelernter J, **Kranzler HR.** Genetics of addiction. In Galanter M, Kleber HD (Eds) *Textbook of Substance Abuse Treatment*, 4th Edition, Washington, DC: American Psychiatric Press, Inc., 2008, pp. 17-27.
73. Knapp CM, Ciraulo DA, **Kranzler HR.** Neurobiology of alcohol. In Galanter M,

- Kleber HD (Eds) *Textbook of Substance Abuse Treatment*, 4th Edition, Washington, DC: American Psychiatric Press, Inc., 2008, pp. 111-127.
74. **Kranzler HR**. Update on medications to treat addictive disorders. *Connecticut Medicine* 72:281-282, 2008.
 75. **Kranzler HR**, Li T-K. What is addiction? *Alcohol Research and Health* 31: 92-95, 2008.
 76. Arias AJ, **Kranzler HR**. Treatment of co-occurring alcohol and other drug use disorders. *Alcohol Research and Health* 31:155-167, 2008.
 77. Tang Y, Gelernter J, **Kranzler HR**, Cubells JF. Non-drug addictive disorders in cocaine-dependent subjects—A response to Merlo et al., *American Journal on Addictions*, 17:249-250, 2008.
 78. **Kranzler HR**, Ciraulo D, Jaffe JH. Medications for use in alcohol rehabilitation. In Ries R, Fiellin D, Miller S, Saitz R (Eds) *Principles of Addiction Medicine*, 4th Edition, Baltimore: Lippincott, Williams, and Wilkins, 2009.
 79. Enoch M-A, Johnson J, George DT, Schumann G, Moss H, **Kranzler HR**, Goldman D. Ethical considerations for administering alcohol or alcohol cues to treatment-seeking alcoholics in a research setting: Can the benefits to society outweigh the risks to the individual? *Alcoholism: Clinical and Experimental Research*, 33:1508-1512, 2009. (PMCID: PMC2746026)
 80. Gelernter J, **Kranzler HR**. Genetics of alcohol dependence. *Human Genetics*, 126:91-99, 2009. (PMCID: PMC3773848)
 81. Oncken C, **Kranzler HR**. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? *Nicotine & Tobacco Research*, 11:1265-1273, 2009. (PMCID: PMC2762929)
 82. Gelernter J, **Kranzler HR**. Genetics of drug dependence. *Dialogues in Clinical Neuroscience*. 12:77-84, 2010. (PMCID: PMC3181942)
 83. Sen S, **Kranzler HR**, Krystal JH, Speller H, Chan G, Gelernter J, Guille C. A prospective cohort study investigating factors associated with depression during medical internship—In reply to Kendler. *Archives of General Psychiatry*, 67:568-569, 2010.
 84. Johnson BA, Messing RO, Charness ME, Crabbe JC, Goldman MS, Harris RA, **Kranzler HR**, Mitchell MC Jr., Nixon SJ, Riley EP, Schuckit MA, Sher KJ, Thomas JD. Should the reorganization of addiction-related research across the National Institutes of Health be structural?—The devil is truly in the details, *Alcoholism: Clinical and Experimental Research*, 35:572-580, 2011. (PMCID: PMC3098615)
 85. Johnson BA, Messing R, Charness ME, Crabbe JC, Goldman M, Harris RA, **Kranzler H**, Mitchell, M, Nixon SJ, Riley E, Schuckit M, Sher K, Thomas J. How should addiction-related research at the National Institutes of Health Be Reorganized? *Frontiers in Psychiatry*, 2:2, 2011. (PMCID: PMC3098615)
 86. Hernandez-Avila C, **Kranzler HR**. Alcohol use disorders. In Ruiz P, Strain E (Eds) *Substance Abuse: A Comprehensive Textbook*, 5th Edition, Philadelphia: Lippincott

Williams & Wilkins, 2011, pp. 138-160.

87. Chang S-C, Xie P, Anton RF, De Vivo I, Farrer LA, **Kranzler HR**, Oslin D, Purcell SM, Roberts AL, Smoller JW, Uddin M, Gelernter J, Koenen KC. No association between *ADCYAP1R1* and post-traumatic stress disorder in two independent samples. *Molecular Psychiatry*, 17:239-41, 2012.
88. Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, **Kranzler HR**, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D, and the ACTIVE Workgroup. The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and goals for assessing important and salient issues for medications development in alcohol use disorders, *Neuropsychopharmacology*, 37:402-11, 2012. (PMCID: PMC3242301).
89. Sun J, Bi J, **Kranzler HR**, A multi-objective program for quantitative subtyping of clinically relevant phenotypes. *Proceedings of IEEE International Conference on Bioinformatics and Biomedicine*, pp. 256-261, 2012.
90. Sun J, Bi J, **Kranzler HR**. Quadratic optimization to identify highly heritable quantitative traits from complex phenotypic features. *Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining*. New York: Association for Computing Machinery, pp. 811-819, 2013.
91. Sun J, Bi J, **Kranzler HR**. Multi-view biclustering for genotype-phenotype association studies of complex diseases. *Proceedings of IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, pp. 316-321, 2013.
92. Leach D, **Kranzler HR**. An interpersonal model of addiction relapse. *Addictive Disorders and Their Treatment*, 12:183-192, 2013. (PMCID: PMC3905329)
93. **Kranzler HR**, Knapp C, Ciraulo D. Pharmacotherapy of alcoholism. In **Kranzler HR**, Ciraulo D, Zindel L (Eds), *Clinical Manual of Addiction Psychopharmacology*, 2nd ed., Washington, DC: American Psychiatric Press, Inc., 2014, pp. 1-69.
94. Zindel L, **Kranzler HR**. Pharmacotherapy of alcohol use disorders: Seventy-five years of progress. *Journal of Studies on Alcohol and Drugs*, Suppl. 17:79-88, 2014.
95. **Kranzler HR**, Zindel LR. Topiramate and heavy drinking: Implications for personalized medicine. *Psychiatric Times*. April 28, 2014.
96. Myrick H, **Kranzler HR**, Ciraulo DA, Saxon AJ, Jaffe JH. Medications for use in alcohol rehabilitation. In Ries RK, Fiellin DA, Miller SC, Saitz R (Eds), *The ASAM Principles of Addiction Medicine*, 5th ed., Philadelphia: Wolters Kluwer, 2014, pp. 713-726.
97. **Kranzler HR**. Commentary on Garbutt et al. (2014): Can we predict who benefits from naltrexone in the treatment of alcohol dependence? *Addiction*, 109:1285-6, 2014. (PMCID: PMC4154559)
98. **Kranzler HR**. *ACER: Quo Vadis? Alcoholism: Clinical and Experimental Research*, 38:2159, 2014. (Editorial)
99. Sun J, Bi J, **Kranzler HR**. Identifying heritable composite traits from multivariate phenotypes using genome-wide SNPs. *Proceedings of the IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, pp. 340-344, 2014.

100. Gelernter J, **Kranzler HR**. Genetics of addiction. In Galanter M, Kleber HD (Eds) *Textbook of Substance Abuse Treatment, 5th Edition*, Washington, DC: American Psychiatric Press, Inc., pp. 25-45, 2015.
101. McKay JR, **Kranzler HR**, Kampman KM, Ashare RL, Schnoll RA. Psychopharmacological treatments for substance use disorders. In Nathan PE, Gorman JM (Eds), *Treatments that Work*. Oxford University Press, 2015, pp. 763-800.
102. **Kranzler HR**. Endorsement of the CONSORT Principles in Reporting Alcohol Clinical Trials in *ACER, Alcoholism: Clinical and Experimental Research*, 39:1556, 2015. (Editorial)
103. Sulovari A, **Kranzler HR**, Farrer LA, Gelernter J, Li D. Further analyses support the association between light eye color and alcohol dependence. *American Journal of Medical Genetics B (Neuropsychiatric Genetics)*, 168:757-60, 2015. (Response to Letter)
104. **Kranzler HR**. New Initiatives for Alcoholism: Clinical and Experimental Research. *Alcoholism: Clinical and Experimental Research* 40:652, 2016. (Editorial)
105. Soyka M, **Kranzler HR**, Hesselbrock V, Kasper S, Mutschler J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. *World Journal of Biological Psychiatry* 18:86-119, 2017. (PMCID: PMC28006997)
106. **Kranzler HR**. New and revised policies for Alcoholism: Clinical and Experimental Research (ACER). *Alcoholism: Clinical and Experimental Research* 42:1570-1571, 2018. (Editorial)

SCIENTIFIC ADVISORY BOARDS

Medical University of South Carolina, Charleston Alcohol Research Center (1999–present, Chair 2012–2014, Co-Chair 2014–present)

Yale University; Psychotherapy Development Research Center (2004–2010)

Yale University; Mental Illness Research, Education and Clinical Center (2007–2010)

University of Connecticut Health Center, Alcohol Research Center (2011–present)

Yale University, Center for the Translational Neuroscience of Alcoholism (2014–2015)

GRANT REVIEWS

ABMRF/The Foundation for Alcohol Research, Behavioral and Social Advisory Council (April 2008–2011)

National Institute on Alcohol Abuse and Alcoholism (NIAAA) Clinical and Treatment Subcommittee (AA-3): Member, June 2000-July 2002; Chair, October 2002-July 2004; multiple subsequent *ad hoc* reviews

NIAAA Alcohol Research Centers Program (*ad hoc*)

NIAAA Special Review Committee: Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS: July 2009

National Institute on Drug Abuse (NIDA) Drug Abuse Research Centers Program (*ad hoc*)

NIDA Translational Avant Garde Pre-application Review: May 2010

NIDA Clinical Trials Network Protocol Review Board: January 2012–present

National Center for Research Resources (General Clinical Research Centers Program; *ad hoc*)

Department of Veterans Affairs (Merit Review Grants Program, *ad hoc*)

Henry Ford Hospital Research Program (*ad hoc*)

Medical Research Council of Canada (*ad hoc*)

United States Department of Defense (*ad hoc*)

Ontario Mental Health Foundation (*ad hoc*)

PROFESSIONAL ORGANIZATIONS

American College of Neuropsychopharmacology
Alcohol Clinical Trials Initiative (2008–2013)
Human Subjects Committee (2008–2009)
Program Committee, Annual Meeting (2011–2014)

College on Problems of Drug Dependence

International Society for Biomedical Research on Alcoholism

Research Society on Alcoholism
Planning Committee, Annual Meeting [2000, 2009, 2010, 2012 (Co-Chair)]
Chair, Fundraising Committee (2005–2009)
Board of Directors (2007–present)

World Federation of Societies of Biological Psychiatry
Chair, Task Force on Treatment Guidelines for Substance Use Disorders (2007–present)